[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2913
6. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, Vora A, Mitchell CD, Harrison CJ: Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol; 2010 May;11(5):429-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.
  • BACKGROUND: Chromosomal abnormalities in childhood acute lymphoblastic leukaemia are well established disease markers and indicators of outcomes.
  • METHODS: We analysed cytogenetic data from 1725 children with B-cell precursor acute lymphoblastic leukaemia who were included in the UK Medical Research Council ALL97/99 study and followed up for a median time of 8.2 years.
  • FUNDING: Leukaemia and Lymphoma Research (LLR).
  • [MeSH-major] Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Humans. Infant. Prognosis. Survival Analysis

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet Oncol. 2010 May;11(5):403-4 [20409755.001]
  • [ErratumIn] Lancet Oncol. 2010 Jun;11(6):516
  • (PMID = 20409752.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130; United Kingdom / Medical Research Council / / MC/ U137686856
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, Kooi C, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, Horstmann M, Petricoin EF 3rd, Pieters R, Meijerink JP: NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia; 2010 Dec;24(12):2014-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.
  • Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW7 is a frequent phenomenon in T-cell acute lymphoblastic leukemia (T-ALL).
  • We retrospectively investigated the relevance of NOTCH1/FBXW7 mutations for pediatric T-ALL patients enrolled on Dutch Childhood Oncology Group (DCOG) ALL7/8 or ALL9 or the German Co-Operative Study Group for Childhood Acute Lymphoblastic Leukemia study (COALL-97) protocols.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prednisone / therapeutic use. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Child. Female. Gene Rearrangement. Homeodomain Proteins / genetics. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2010 Dec;24(12):2003-4 [21157484.001]
  • (PMID = 20861909.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 0 / TLX3 protein, human; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases; VB0R961HZT / Prednisone
  •  go-up   go-down


8. Vorwerk P, Mohnike K, Wex H, Röhl FW, Zimmermann M, Blum WF, Mittler U: Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab; 2005 May;90(5):3022-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk.
  • Despite remarkable advances in the clinical outcome of most children with acute lymphoblastic leukemia, a substantial number of patients ultimately relapse or suffer from side effects of treatment.
  • Serum levels of IGF-I, IGF-II, IGF binding protein (IGFBP)-1, IGFBP-2, and IGFBP-3 were measured in 162 children with acute lymphoblastic leukemia treated by the Berlin Frankfurt Munster Study Group.
  • [MeSH-major] Insulin-Like Growth Factor Binding Protein 2 / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Insulin-Like Growth Factor I / analysis. Insulin-Like Growth Factor II / analysis. Male. Platelet Count. Prognosis. Prospective Studies. Recurrence. Risk

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15687344.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


9. Berretta R, Barone A, Rolla M, Bertolini P, Nardelli GB: Isolated ovarian relapse of pre-B acute lymphoblastic leukemia: a case report. J Pediatr Adolesc Gynecol; 2009 Aug;22(4):e65-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated ovarian relapse of pre-B acute lymphoblastic leukemia: a case report.
  • BACKGROUND: Acute lymphoblastic leukemia is a malignant disease of the bone marrow in which early lymphoid precursors proliferate and replace normal marrow hematopoietic cells, resulting in a marked decrease in the production of normal blood cells.
  • CONCLUSION: In contrast to testicular relapse, ovarian relapses in acute lymphoblastic leukemia are rarely reported.
  • [MeSH-major] Ovarian Neoplasms / secondary. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19493520.001).
  • [ISSN] 1873-4332
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Papadia C, Naves LA, Costa SS, Vaz JA, Domingues L, Casulari LA: Incidence of obesity does not appear to be increased after treatment of acute lymphoblastic leukemia in Brazilian children: role of leptin, insulin, and IGF-1. Horm Res; 2007;68(4):164-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of obesity does not appear to be increased after treatment of acute lymphoblastic leukemia in Brazilian children: role of leptin, insulin, and IGF-1.
  • BACKGROUND/AIMS: It has been reported that children treated for acute lymphoblastic leukemia (ALL) in developed countries show an increased risk of overweight and obesity in adolescence and adulthood.
  • METHODS: Two groups of subjects were studied: 27 survivors of childhood ALL (14.0 +/- 4.2 years old; post-treatment interval 8.6 +/- 3.9 years) (ALL group) and 17 healthy subjects (12.8 +/- 4 years old) (control group) selected on the basis of their kinship with the patients.
  • CONCLUSION: The data indicate the presence of alterations in the homeostatic regulatory mechanisms controlling body weight in Brazilian patients treated for ALL in childhood, still, it did not lead to obesity in the absence of favorable environmental conditions.
  • [MeSH-major] Insulin / physiology. Insulin-Like Growth Factor I / physiology. Leptin / physiology. Obesity / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Body Mass Index. Brazil. Child. Female. Follow-Up Studies. Humans. Incidence. Male. Waist-Hip Ratio


11. Torres T JP, Concha V E, López G JP, Cofre G J: [Acute retinal necrosis in an acute leukemia pediatric patient]. Rev Chilena Infectol; 2007 Aug;24(4):323-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute retinal necrosis in an acute leukemia pediatric patient].
  • [Transliterated title] Necrosis retinal aguda en un paciente pediátrico con leucemia aguda.
  • Acute retinal necrosis (ARN) is a serious condition that can impair vision.
  • We present a 4 years old patient with high risk acute leukemia, whom during a course of intense chemotherapy acquired chickenpox with visceral involvement that affected the retina, causing unilateral blindness.
  • [MeSH-major] Chickenpox / complications. Immunocompromised Host. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Retinal Necrosis Syndrome, Acute / virology
  • [MeSH-minor] Antiviral Agents / therapeutic use. Child, Preschool. Humans. Male

  • MedlinePlus Health Information. consumer health - Chickenpox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728923.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


12. Tham EH, Tay SK, Low PS: Factors predictive of outcome in childhood stroke in an Asian population. Ann Acad Med Singapore; 2009 Oct;38(10):876-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predictive of outcome in childhood stroke in an Asian population.
  • The aim of this study was to evaluate the epidemiology of childhood stroke in a tertiary paediatric unit in Singapore and to assess factors influencing outcome in these children.
  • MATERIALS AND METHODS: A retrospective case-note review of all childhood strokes presenting to the Children's Medical Institute (CMI) at the National University Hospital (NUH), Singapore between October 1999 and May 2006.
  • [MeSH-minor] Adolescent. Age Factors. Asian Continental Ancestry Group. Brain Ischemia / epidemiology. Brain Ischemia / etiology. Brain Ischemia / rehabilitation. Cerebral Hemorrhage / etiology. Child. Child, Preschool. Developmental Disabilities / etiology. Female. Humans. Infant. Intracranial Arteriovenous Malformations / complications. Length of Stay / statistics & numerical data. Male. Neuropsychological Tests. Prognosis. Retrospective Studies. Risk Assessment. Risk Factors. Singapore / epidemiology. Treatment Outcome. Vascular Diseases / complications

  • MedlinePlus Health Information. consumer health - Stroke.
  • MedlinePlus Health Information. consumer health - Stroke Rehabilitation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890579.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


13. Karrman K, Forestier E, Heyman M, Andersen MK, Autio K, Blennow E, Borgström G, Ehrencrona H, Golovleva I, Heim S, Heinonen K, Hovland R, Johannsson JH, Kerndrup G, Nordgren A, Palmqvist L, Johansson B, Nordic Society of Pediatric Hematology, Oncology (NOPHO), Swedish Cytogenetic Leukemia Study Group (SCLSG), NOPHO Leukemia Cytogenetic Study Group (NLCSG): Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome. Genes Chromosomes Cancer; 2009 Sep;48(9):795-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome.
  • Clinical characteristics and cytogenetic aberrations were ascertained and reviewed in a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias (T-ALLs) diagnosed between 1992 and 2006 in the Nordic countries.
  • In conclusion, in this large series of childhood T-ALLs from the Nordic countries, the cytogenetic findings were not associated with risk of therapy failure with the exception of the TCR;other group.
  • [MeSH-major] Chromosome Aberrations. Gene Rearrangement, T-Lymphocyte. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Adolescent. Chi-Square Distribution. Child. Child, Preschool. Cohort Studies. Cytogenetic Analysis. Female. Humans. Kaplan-Meier Estimate. Male. Multivariate Analysis. Prognosis. Proportional Hazards Models

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530250.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


1
Advertisement
4. Hernández Sánchez JE, Gómez Vegas A, Blázquez Izquierdo J, Grimalt Alvarez J, Pérez Contín MJ, Rabadán Marina M, San José Manso L, Alonso Prieto M, Pérez Romero N, Silmi Moyano A: [En bloc transplantation of pediatric donor kidneys to adult receptors]. Arch Esp Urol; 2007 Mar;60(2):137-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [En bloc transplantation of pediatric donor kidneys to adult receptors].
  • [Transliterated title] Trasplante en bloque de riñones procedentes de donantes pediatricos en receptores adultos.
  • OBJECTIVES: Analysis of all pediatric donor en bloc transplants to adult receptors performed in our department.
  • RESULTS: There were significant differences in terms of nonfunctioning kidneys and delayed graft function, more frequent in pediatric en bloc and adult transplants, respectively.
  • Pediatric kidneys provided better renal function and less proteinuria.
  • One and five-year graft survivals were 83.56% and 8 1.47% for pediatric donor kidneys, and 91.50% and 86.99% for adult donor kidneys.
  • CONCLUSIONS: Pediatric donor en bloc transplants have an excellent survival and function in the middle and long-term.
  • Vascular complications are the main cause of pediatric donor graft loss.
  • The adoption of a pediatric donor en bloc transplant program increases the transplant activity.
  • [MeSH-minor] Adult. Age Factors. Child. Child, Preschool. Female. Graft Survival. Humans. Immunosuppressive Agents / therapeutic use. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Postoperative Complications / epidemiology. Retrospective Studies. Spain. Survival Analysis. Tissue Donors. Tissue and Organ Procurement. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484481.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


15. Kamiya H, Nakano T, Inoue M, Kamiya H, Abd TT, Patel M, Orenstein WA, Parashar UD: A retrospective evaluation of hospitalizations for acute gastroenteritis at 2 sentinel hospitals in central Japan to estimate the health burden of rotavirus. J Infect Dis; 2009 Nov 1;200 Suppl 1:S140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective evaluation of hospitalizations for acute gastroenteritis at 2 sentinel hospitals in central Japan to estimate the health burden of rotavirus.
  • METHODS: To describe the epidemiology of severe rotavirus disease among Japanese children aged <5 years, we examined retrospective demographic, clinical, and laboratory data from the period 2003-2007 for children hospitalized with acute gastroenteritis (AGE) at 2 sentinel hospitals in Japan.
  • RESULTS: At each of the 2 hospitals, 17%-21% of all pediatric hospitalizations were for AGE.
  • [MeSH-minor] Acute Disease. Humans. Japan / epidemiology. Retrospective Studies. Seasons

  • MedlinePlus Health Information. consumer health - Gastroenteritis.
  • MedlinePlus Health Information. consumer health - Rotavirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817592.001).
  • [ISSN] 1537-6613
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Yanke BV, Horowitz M: Safety of the Veress needle in pediatric laparoscopy. J Endourol; 2007 Jul;21(7):695-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of the Veress needle in pediatric laparoscopy.
  • PURPOSE: To better establish the complication rate with the Veress needle technique for establishing a pneumoperitoneum in pediatric laparoscopy.
  • PATIENTS AND METHODS: We reviewed all pediatric laparoscopy cases performed by a single surgeon from 1996 to 2003.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705752.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Vijayakrishnan J, Houlston RS: Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica; 2010 Aug;95(8):1405-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.
  • To evaluate the contribution of candidate gene association studies to the understanding of genetic susceptibility to childhood acute lymphoblastic leukemia we conducted a systematic review and meta-analysis of published studies (January 1996-July 2009).
  • We identified 47 studies of polymorphic variation in 16 genes and acute lymphoblastic leukemia risk.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Genome-Wide Association Study / methods. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Humans. Odds Ratio. PubMed. Risk Factors


18. Cheng Q, Evans WE: Cancer pharmacogenomics may require both qualitative and quantitative approaches. Cell Cycle; 2005 Nov;4(11):1506-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significant advances have been achieved in event-free survival of patients with many types of cancer (most dramatically childhood acute lymphoblastic leukemia, ALL) through a better understanding of the pathobiology of human cancers, the cellular mechanisms of cancer chemotherapy, and the determinants of inter-individual differences in drug effects and treatment response.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258271.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / R01 CA78224; United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 53
  •  go-up   go-down


19. Stanulla M, Schünemann HJ: Thioguanine versus mercaptopurine in childhood ALL. Lancet; 2006 Oct 14;368(9544):1304-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thioguanine versus mercaptopurine in childhood ALL.
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thioguanine / therapeutic use
  • [MeSH-minor] Child. Disease-Free Survival. Humans. Randomized Controlled Trials as Topic

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet. 2006 Oct 14;368(9544):1339-48 [17046466.001]
  • (PMID = 17046444.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


20. Sala A, Rossi E, Antillon F: Nutritional status at diagnosis in children and adolescents with cancer in the Asociacion de Hemato-Oncologia Pediatrica de Centro America (AHOPCA) countries: preliminary results from Guatemala. Pediatr Blood Cancer; 2008 Feb;50(2 Suppl):499-501; discussion 517
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutritional status at diagnosis in children and adolescents with cancer in the Asociacion de Hemato-Oncologia Pediatrica de Centro America (AHOPCA) countries: preliminary results from Guatemala.
  • In particular, the proportions of patients with non-lymphoblastic leukemias and myelodysplasia (MDS) with moderate and severe malnutrition were 73% and 9% respectively; higher than that in the population with acute lymphoblastic leukemia (ALL), P = 0.0493.
  • [MeSH-minor] Adolescent. Anthropometry. Child. Guatemala / epidemiology. Humans

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18064663.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


21. Bhatt UK, Gregory ME, Madi MS, Fraser M, Woodruff GH: Sequential leukemic infiltration and human herpesvirus optic neuropathy in acute lymphoblastic leukemia. J AAPOS; 2008 Apr;12(2):200-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential leukemic infiltration and human herpesvirus optic neuropathy in acute lymphoblastic leukemia.
  • Leukemic infiltration is a common cause of optic disk swelling in a patient with acute lymphoblastic leukemia (ALL).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329931.001).
  • [ISSN] 1528-3933
  • [Journal-full-title] Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
  • [ISO-abbreviation] J AAPOS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Adelman AS, Groves FD, O'Rourke K, Sinha D, Hulsey TC, Lawson AB, Wartenberg D, Hoel DG: Residential mobility and risk of childhood acute lymphoblastic leukaemia: an ecological study. Br J Cancer; 2007 Jul 2;97(1):140-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residential mobility and risk of childhood acute lymphoblastic leukaemia: an ecological study.
  • We conducted an ecological analysis of childhood acute lymphoblastic leukaemia-incidence data from children <or=5 years old during 1992-1998 from the Surveillance, Epidemiology, and End Results Program in 200 counties and Hawaii.
  • [MeSH-major] Population Dynamics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Child, Preschool. Female. Hawaii. Humans. Incidence. Income. Male. Poverty. Risk Factors. Sex Characteristics. United States. Urban Population

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Dec;83(11):1559-64 [11076669.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):526-31 [15951671.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1428-37 [11821358.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1057-64 [15184264.001]
  • [Cites] J Natl Cancer Inst. 1971 Sep;47(3):501-9 [5157573.001]
  • [Cites] Med J Aust. 1980 Aug 9;2(3):154-5 [6932561.001]
  • [Cites] J Epidemiol Community Health. 1981 Dec;35(4):245-50 [7338698.001]
  • [Cites] Br J Cancer. 1982 Oct;46(4):640-5 [6958309.001]
  • [Cites] Epidemiol Rev. 1985;7:22-48 [3902495.001]
  • [Cites] Pediatrie. 1988;43(1):59-65 [3387182.001]
  • [Cites] Int J Cancer. 1988 Oct 15;42(4):511-20 [3170025.001]
  • [Cites] Lancet. 1989 Nov 11;2(8672):1145-7 [2572858.001]
  • [Cites] J Public Health Med. 1990;12(2):109-17 [2223195.001]
  • [Cites] Lancet. 1990 Dec 15;336(8729):1461-5 [1979091.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):549-54 [1911197.001]
  • [Cites] Am J Epidemiol. 1992 Oct 15;136(8):916-24 [1456268.001]
  • [Cites] Acta Haematol. 1992;88(2-3):58-60 [1466202.001]
  • [Cites] J Public Health Med. 1993 Mar;15(1):9-15 [8471307.001]
  • [Cites] BMJ. 1993 Mar 20;306(6880):743-8 [8490337.001]
  • [Cites] BMJ. 1995 Mar 25;310(6982):763-8 [7711579.001]
  • [Cites] Cancer Causes Control. 1995 Sep;6(5):383-8 [8547535.001]
  • [Cites] Paediatr Perinat Epidemiol. 1996 Oct;10(4):411-7 [8931055.001]
  • [Cites] BMJ. 1996 Nov 23;313(7068):1297-300 [8942689.001]
  • [Cites] Br J Cancer. 1997;75(3):457-63 [9020498.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):239-45 [9134248.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):842-9 [9514068.001]
  • [Cites] Cancer Causes Control. 1998 May;9(3):285-98 [9684709.001]
  • [Cites] Int J Epidemiol. 1998 Aug;27(4):587-91 [9758111.001]
  • [Cites] Br J Cancer. 1999 Jan;79(1):30-3 [10408689.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):144-51 [10487626.001]
  • [Cites] Cancer. 1959 Mar-Apr;12(2):351-8 [13638954.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):2084-8 [15886703.001]
  • [Cites] Cancer Causes Control. 2001 Aug;12(6):483-90 [11519756.001]
  • (PMID = 17533404.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359674
  •  go-up   go-down


23. Castagnetti M, Sainati L, Giona F, Varotto S, Carli M, Rigamonti W: Conservative management of priapism secondary to leukemia. Pediatr Blood Cancer; 2008 Sep;51(3):420-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative management of priapism secondary to leukemia.
  • We report four cases of leukemia (three chronic myeloid and one T-cell acute lymphoblastic) presenting with priapism in children 9- to 13-year old.
  • Based on these cases, conservative management of priapism in children with leukemia might be adequate and not lead to long-term erectile dysfunction.
  • [MeSH-major] Leukemia / complications. Priapism / etiology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Disease Management. Erectile Dysfunction / drug therapy. Erectile Dysfunction / prevention & control. Humans. Male

  • Genetic Alliance. consumer health - Priapism.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18506758.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Li F, Fridley BL, Matimba A, Kalari KR, Pelleymounter L, Moon I, Ji Y, Jenkins GD, Batzler A, Wang L, Weinshilboum RM: Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos; 2010 Dec;38(12):2329-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thiopurine drugs such as 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used to treat acute lymphoblastic leukemia of childhood.

  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827859351 for PMID:20855458 [PharmGKB] .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pflugers Arch. 2004 Feb;447(5):735-43 [12838422.001]
  • [Cites] Cancer Cell. 2009 Sep 8;16(3):259-66 [19732725.001]
  • [Cites] Biochemistry. 1969 Jan;8(1):122-30 [4304985.001]
  • [Cites] Biochem Pharmacol. 1969 Apr;18(4):936-8 [5788533.001]
  • [Cites] Am J Hum Genet. 1980 Sep;32(5):651-62 [7191632.001]
  • [Cites] Br J Clin Pharmacol. 1983 Oct;16(4):359-63 [6578834.001]
  • [Cites] Clin Pharmacol Ther. 1987 Jan;41(1):18-25 [3467886.001]
  • [Cites] Lancet. 1987 Dec 19;2(8573):1471 [2892037.001]
  • [Cites] J Chromatogr. 1987 Dec 25;423:169-78 [3443647.001]
  • [Cites] Biomed Chromatogr. 1990 Mar;4(2):47-51 [2350596.001]
  • [Cites] J Biol Chem. 1990 Dec 25;265(36):22210-6 [2266122.001]
  • [Cites] J Chromatogr. 1991 Nov 15;571(1-2):149-56 [1810943.001]
  • [Cites] Biochem J. 1992 Jul 15;285 ( Pt 2):345-65 [1637327.001]
  • [Cites] Eur J Clin Pharmacol. 1992;43(4):329-39 [1451710.001]
  • [Cites] J Chromatogr. 1992 Nov 27;583(1):83-90 [1484095.001]
  • [Cites] Mol Pharmacol. 1993 Jun;43(6):878-87 [8316220.001]
  • [Cites] DNA Cell Biol. 1996 Jan;15(1):17-30 [8561894.001]
  • [Cites] Clin Chem. 1998 Dec;44(12):2511-5 [9836719.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1048-51 [10470083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9394-9 [15967990.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1778-85 [15905191.001]
  • [Cites] Oncogene. 2006 Mar 13;25(11):1629-38 [16550163.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15 [16530731.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2006;7:223-45 [16948615.001]
  • [Cites] Am J Hum Genet. 1996 Apr;58(4):694-702 [8644731.001]
  • [Cites] Clin Chem. 1998 Mar;44(3):551-5 [9510860.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1998 Sep 25;716(1-2):392-6 [9824258.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8375-81 [10722669.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5810-6 [11479220.001]
  • [Cites] Mol Pharmacol. 2002 Dec;62(6):1321-31 [12435799.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Aug 15;18(4):395-400 [12940924.001]
  • [Cites] Pharmacogenetics. 2003 Sep;13(9):555-64 [12972954.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63 [17537913.001]
  • [Cites] Leuk Res. 2008 May;32(5):799-809 [17996297.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3161-8 [18451141.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):4983-9 [18593894.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7050-8 [18757419.001]
  • [Cites] Pflugers Arch. 2004 Feb;447(5):728-34 [12856181.001]
  • (PMID = 20855458.001).
  • [ISSN] 1521-009X
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM028157; United States / NCI NIH HHS / CA / R01-CA132780; United States / NIGMS NIH HHS / GM / R01-GM28157; United States / NIGMS NIH HHS / GM / U01 GM061388; United States / NCI NIH HHS / CA / R01 CA132780; United States / NCI NIH HHS / CA / K22 CA130828; United States / NIGMS NIH HHS / GM / GM061388-10; United States / NCI NIH HHS / CA / K22-CA130828; United States / NCI NIH HHS / CA / R01 CA132780-04; United States / NIGMS NIH HHS / GM / R01 GM028157-30; United States / NIGMS NIH HHS / GM / U01 GM061388-10; United States / NIGMS NIH HHS / GM / U01-GM61388; United States / NCI NIH HHS / CA / R01 CA138461; United States / NCI NIH HHS / CA / R01-CA138461
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCC4 protein, human; 0 / Multidrug Resistance-Associated Proteins; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase; EC 3.1.3.5 / 5'-Nucleotidase; FTK8U1GZNX / Thioguanine
  • [Other-IDs] NLM/ PMC2993460
  •  go-up   go-down


25. Bechtold S, Putzker S, Birnbaum J, Schwarz HP, Netz H, Dalla Pozza R: Impaired bone geometry after heart and heart-lung transplantation in childhood. Transplantation; 2010 Nov 15;90(9):1006-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired bone geometry after heart and heart-lung transplantation in childhood.
  • BACKGROUND: Impaired bone health has been advocated after solid organ transplantation in adult and pediatric patients.
  • CONCLUSION: After heart transplantation and heart-lung transplantation in childhood, all our patients showed altered bone geometry and low muscle CSA.
  • [MeSH-minor] Adolescent. Adult. Body Mass Index. Child. Diaphyses / anatomy & histology. Female. Forearm. Glucocorticoids / therapeutic use. Humans. Infant. Male. Radius / anatomy & histology


26. Renbarger JL, McCammack KC, Rouse CE, Hall SD: Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer; 2008 Apr;50(4):769-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients.
  • BACKGROUND: This report examines the association between race and vincristine-associated neurotoxicity in pediatric patients with precursor B cell acute lymphoblastic leukemia (preB ALL).
  • PROCEDURE: A retrospective analysis of vincristine-related side effects in pediatric patients treated for preB ALL was performed.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Continental Population Groups / ethnology. Neurotoxicity Syndromes / ethnology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vincristine / adverse effects
  • [MeSH-minor] African Americans. Child. Child, Preschool. European Continental Ancestry Group. Female. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18085684.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR019956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


27. van Scherpenzeel Thim V, Remacle S, Picard J, Cornu G, Gofflot F, Rezsohazy R, Verellen-Dumoulin C: Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function. Hum Mutat; 2005 Apr;25(4):384-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function.
  • The molecular basis of susceptibility to childhood malignant hemopathy remains largely unknown.
  • We aimed to explore the possibility that germline alterations of HOX genes might be involved in childhood acute lymphoid malignancies.
  • A cohort of 86 children diagnosed with acute lymphoid malignancy was studied, 20 of them concurrently presenting a congenital anomaly of the skeleton.
  • While 13 changes were also observed in healthy controls, three variants were exclusively found in acute lymphoid malignancy cases.
  • These comprised the germline c.242A>T (p.Glu81Val) missense mutation of HOXD4, detected in two children diagnosed with acute lymphoblastic leukemia (ALL).
  • Functional analysis of the murine Hoxd4 homolog revealed that mutant Hoxd4 protein had lower transcriptional activity than wild-type protein in vitro.
  • The p.Glu81Val mutation of HOXD4 thus results in a partial loss-of-function, which might be involved in childhood ALL.
  • [MeSH-major] Germ-Line Mutation. Homeodomain Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Animals. Child. Child, Preschool. Cohort Studies. DNA Mutational Analysis. Female. Haplotypes. Humans. Infant. Male. Mice. Molecular Sequence Data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776434.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 142981; RefSeq/ NM/ 014621
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HOXD1 protein, human; 0 / Homeodomain Proteins; 0 / Hoxd4 protein, mouse; 0 / Transcription Factors
  •  go-up   go-down


28. Seibel NL: Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls. Hematology Am Soc Hematol Educ Program; 2008;:374-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls.
  • Survival of children with acute lymphoblastic leukemia (ALL) is often described as the success story for oncology.
  • Fifty years ago a pediatric oncologist would have never considered using the term "cure" in a discussion with a family whose child was diagnosed with ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074113.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 45
  •  go-up   go-down


29. Xu XJ, Tang YM, Song H, Shi SW, Yang SL, Shen HQ, Wei J, Xu WQ, Pan BH, Zhao FY: [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance]. Zhonghua Er Ke Za Zhi; 2010 Mar;48(3):180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
  • OBJECTIVE: Monitoring of minimal residual disease (MRD) is proven to be increasingly valuable for predicting relapse and outcome of childhood acute lymphoblastic leukemia (ALL) and is used to identify patients' risk groups in several current clinical trials.
  • The aim of this study was to investigate the predictive values of different MRD levels detected at different chemotherapy phases in childhood ALL.
  • All the patients were treated with modified National Protocol of Childhood ALL in China 1997.
  • All samples were stained with a panel of four colour combinations of fluorochrome conjugated monoclonal antibodies according to the leukemia-associated immunophenotype (LAIP) defined at diagnosis and analyzed by multi-parametric flow cytometry.
  • CONCLUSION: Dynamic MRD detection by multi-parametric flow cytometry is highly predictive of outcome for childhood ALL, and the cut-off values at different time points were different.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Infant, Newborn. Male. Neoplasm, Residual. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426951.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


30. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR, Children's Oncology Group: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med; 2009 Jan 29;360(5):470-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
  • BACKGROUND: Despite best current therapy, up to 20% of pediatric patients with acute lymphoblastic leukemia (ALL) have a relapse.
  • This predictor was strongly associated with alteration of IKZF1, a gene that encodes the lymphoid transcription factor IKAROS.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827854863 for PMID:19129520 [PharmGKB] .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Massachusetts Medical Society
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4434-41 [15231652.001]
  • [Cites] Cell. 1995 Oct 20;83(2):289-99 [7585946.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5358-69 [8895580.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):368-76 [15599932.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Haematologica. 2006 Jul;91(7):881-5 [16818274.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):240-50 [17658395.001]
  • [Cites] Blood. 2008 Jan 15;111(2):776-84 [17890455.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Cell. 2008 May 16;133(4):727-41 [18485879.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):47-58 [18598943.001]
  • [Cites] Science. 2008 Nov 28;322(5906):1377-80 [19039135.001]
  • [Cites] Cell. 1994 Oct 7;79(1):143-56 [7923373.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] Genes Dev. 2000 Sep 1;14(17):2146-60 [10970879.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Immunol Rev. 2000 Aug;176:141-53 [11043774.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2673-80 [11675337.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2037-45 [12357355.001]
  • [Cites] Immunol Cell Biol. 2003 Jun;81(3):171-5 [12752680.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3084-91 [12915598.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5483-9 [14500810.001]
  • [CommentIn] N Engl J Med. 2009 Jan 29;360(5):524-6 [19131438.001]
  • [CommentIn] N Engl J Med. 2009 Apr 23;360(17):1787; author reply 1787-8 [19387020.001]
  • [CommentIn] Future Oncol. 2009 May;5(4):455-8 [19450174.001]
  • (PMID = 19129520.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413-07; None / None / / U10 CA098413-07; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA86011; United States / NCI NIH HHS / CA / U01 CA114762; United States / NCI NIH HHS / CA / CA114762; United States / NCI NIH HHS / CA / U10 CA098413; United States / NIGMS NIH HHS / GM / U01GM61374; United States / PHS HHS / / N01-C0-12400; United States / NCI NIH HHS / CA / CA098543; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / PHS HHS / / 21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NIGMS NIH HHS / GM / U01 GM061374; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / P30 CA021765-30; United States / NCI NIH HHS / CA / R01 CA086011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / EBF1 protein, human; 0 / IKZF1 protein, human; 0 / PAX5 protein, human; 0 / Trans-Activators; 148971-36-2 / Ikaros Transcription Factor
  • [Other-IDs] NLM/ NIHMS93692; NLM/ PMC2674612
  •  go-up   go-down


31. Tofil NM, Lee White M, Manzella B, McGill D, Zinkan L: Initiation of a pediatric mock code program at a children's hospital. Med Teach; 2009 Jun;31(6):e241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initiation of a pediatric mock code program at a children's hospital.
  • BACKGROUND: Pediatric cardiopulmonary arrests are rare.
  • AIM: The goal was to improve medical caregivers' skills in pediatric resuscitation.
  • METHODS: All pediatric and internal medicine/pediatric (med/peds) residents were anonymously surveyed pre- and post-intervention about confidence level about codes and code skills.
  • Statistical comparisons were made between each resident pre- and post-survey, graduating third-year residents (PGY3s) prior to intervention versus PGY3s with mock codes and pediatric versus med/peds residents.
  • Med/peds residents were significantly more confident in their skills than pediatric residents both pre- (p = 0.041) and post-intervention (p = 0.016).
  • CONCLUSIONS: Pediatric mock codes can improve resident confidence and self-assessment of their resuscitation skills.
  • [MeSH-minor] Adult. Child. Child, Preschool. Data Collection. Educational Status. Female. Hospitals, Pediatric. Humans. Infant. Infant, Newborn. Internal Medicine / education. Male. Models, Educational. Patient Care Team. Pediatrics / education. Self-Assessment

  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • MedlinePlus Health Information. consumer health - CPR.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19811155.001).
  • [ISSN] 1466-187X
  • [Journal-full-title] Medical teacher
  • [ISO-abbreviation] Med Teach
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Mahle WT: Cardiac retransplantation in children. Pediatr Transplant; 2008 May;12(3):274-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To discuss the indications for and outcomes of cardiac retransplantation in childhood.
  • The major challenge of pediatric heart transplantation is graft failure.
  • Retransplantation may be considered in children or young adults who develop graft failure following pediatric heart transplantation.
  • Retransplantation now accounts for 7% of all pediatric transplants.
  • Novel therapies to extend the life of the primary graft and to stratify those at risk of severe graft dysfunction will improve the allocation of scarce organs for pediatric patients who might be candidates for cardiac retransplantation.
  • [MeSH-minor] Child. Heart Diseases / complications. Heart Diseases / therapy. Humans. Immunosuppressive Agents / therapeutic use. Kidney Diseases / complications. Prognosis. Reoperation / methods. Reoperation / statistics & numerical data. Risk. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18435605.001).
  • [ISSN] 1399-3046
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


33. Vila L, Moreno L, Andrés MM, Fernández JM, Verdeguer A, Pérez-Valle S, Sangüesa C, Berbel O, Castel V: Could other viruses cause pediatric posttransplant lymphoproliferative disorder? Clin Transl Oncol; 2008 Jul;10(7):422-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Could other viruses cause pediatric posttransplant lymphoproliferative disorder?
  • METHODS: Case 1 was a 24-month-old boy diagnosed with acute lymphoblastic leukemia who underwent allogeneic stem-cell transplantation (SCT).
  • [MeSH-minor] Child. Child, Preschool. Cytomegalovirus. Cytomegalovirus Infections / complications. Cytomegalovirus Infections / epidemiology. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / epidemiology. Herpesvirus 4, Human. Humans. Infant. Infant, Newborn. Kidney Transplantation / adverse effects. Male. Stem Cell Transplantation / adverse effects. Viral Load

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Transplant. 2001 Aug;5(4):250-7 [11472603.001]
  • [Cites] Herpes. 2003 Dec;10(3):60-5 [14759337.001]
  • [Cites] Am J Transplant. 2004 Feb;4(2):222-30 [14974943.001]
  • [Cites] Blood. 2001 Aug 15;98(4):972-8 [11493441.001]
  • [Cites] J Infect Dis. 1997 Dec;176(6):1462-7 [9395355.001]
  • [Cites] Transplantation. 1999 Dec 27;68(12):1851-4 [10628763.001]
  • [Cites] Transpl Infect Dis. 2001 Jun;3(2):70-8 [11395972.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1065-8 [11374404.001]
  • [Cites] Transplantation. 2002 Jan 15;73(1):100-4 [11792987.001]
  • (PMID = 18628071.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


34. Leung W, Neale G, Behm F, Iyengar R, Finkelstein D, Kastan MB, Pui CH: Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiol; 2010 Jun;34(3):303-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Survivors of childhood acute lymphoblastic leukemia (ALL) are at an increased risk of developing secondary malignant neoplasms.
  • In contrast, patients had lower numbers of all lymphocyte subsets involved in innate immunity (gammadeltaT cells and all NK subsets, including KIR2DL1+ cells, KIR2DL2/L3+ cells, and CD16+ cells), and lower natural cytotoxicity against K562 leukemia cells.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2000 Jan 1;95(1):352-9 [10607724.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):41-9 [11905813.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1036-42 [10973325.001]
  • [Cites] Lancet. 2000 Nov 25;356(9244):1795-9 [11117911.001]
  • [Cites] Science. 2001 Oct 19;294(5542):605-9 [11567106.001]
  • [Cites] Nat Immunol. 2002 Jan;3(1):83-90 [11743585.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):224-7 [7913156.001]
  • [Cites] JAMA. 1994 Nov 9;272(18):1427-32 [7933424.001]
  • [Cites] Nature. 1995 May 11;375(6527):155-8 [7753173.001]
  • [Cites] Biochemistry. 1996 Jun 18;35(24):8035-44 [8672508.001]
  • [Cites] Blood. 2002 May 15;99(10):3661-7 [11986221.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Nat Biotechnol. 2003 Oct;21(10):1233-7 [12960966.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Genome Res. 2004 Feb;14(2):287-95 [14762065.001]
  • [Cites] Genome Res. 2004 Mar;14(3):414-25 [14993208.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4464-71 [15231655.001]
  • [Cites] Blood. 1972 Jul;40(1):42-51 [4624721.001]
  • [Cites] Cancer Res. 1982 Oct;42(10):4289-92 [6955009.001]
  • [Cites] Med Pediatr Oncol. 1986;14(6):295-9 [3466000.001]
  • [Cites] Lancet. 1987 Jan 24;1(8526):190-3 [2880018.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):136-42 [2787477.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):143-51 [2501681.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1348-56 [2072138.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Biomed Pharmacother. 1996;50(3-4):125-31 [8881368.001]
  • [Cites] Immunol Rev. 1997 Dec;160:159-70 [9476674.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Mutat Res. 1998 Dec 3;422(2):213-22 [9838123.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):316-23 [15549093.001]
  • [Cites] Cell. 2005 Feb 25;120(4):497-512 [15734682.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6540-5 [15879158.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1749-54 [15920008.001]
  • [Cites] Nature. 2005 Aug 25;436(7054):1186-90 [15995699.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7936-41 [16258093.001]
  • [Cites] Curr Opin Immunol. 2006 Feb;18(1):31-8 [16337364.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):261-70 [16498454.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10672-7 [16807291.001]
  • [Cites] Semin Cancer Biol. 2006 Oct;16(5):344-7 [16914325.001]
  • [Cites] J Leukoc Biol. 2006 Oct;80(4):915-21 [16877676.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1717-22 [16888619.001]
  • [Cites] Nat Cell Biol. 2008 Jan;10(1):85-92 [18084281.001]
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • (PMID = 20413363.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-24; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / P30 CA-21765-24
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS193817; NLM/ PMC2874127
  •  go-up   go-down


35. Riga M, Korres S, Varvutsi M, Kosmidis H, Douniadakis D, Psarommatis I, Yiotakis I, Ferekidis E: Long-term effects of chemotherapy for acute lymphoblastic leukemia on the medial olivocochlear bundle: effects of different cumulative doses of gentamicin. Int J Pediatr Otorhinolaryngol; 2007 Nov;71(11):1767-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects of chemotherapy for acute lymphoblastic leukemia on the medial olivocochlear bundle: effects of different cumulative doses of gentamicin.
  • OBJECTIVE: The treatment of acute lymphoblastic leukemia (ALL) often combines a neurotoxic chemotherapeutic protocol such as Berlin-Frankfurt-Munster-95 (BFM-95) with gentamicin, an antibiotic known to have an early and quickly reversed impact on olivocochlear reflex in animal studies.
  • [MeSH-major] Anti-Bacterial Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cochlear Nerve / drug effects. Cochlear Nerve / physiopathology. Gentamicins / adverse effects. Hair Cells, Auditory, Inner / drug effects. Nerve Fibers / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Dose-Response Relationship, Drug. Female. Humans. Male. Otoacoustic Emissions, Spontaneous / drug effects. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884185.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Gentamicins
  •  go-up   go-down


36. Chen RL, Chuang SS: Transient spontaneous remission after tumor lysis syndrome triggered by a severe pulmonary infection in an adolescent boy with acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2009 Jan;31(1):76-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient spontaneous remission after tumor lysis syndrome triggered by a severe pulmonary infection in an adolescent boy with acute lymphoblastic leukemia.
  • [MeSH-major] Pneumonia / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Remission, Spontaneous. Tumor Lysis Syndrome / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125097.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


37. Crazzolara R, Bendall L: Emerging treatments in acute lymphoblastic leukemia. Curr Cancer Drug Targets; 2009 Feb;9(1):19-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging treatments in acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is a clonal proliferation of early B- and T-lymphocyte progenitors and results in the accumulation of leukemic blasts in the bone marrow and various extramedullary sites.
  • Despite current treatment protocols achieving rapid cytoreduction in the vast majority of patients, serious acute and late complications are frequent and resistance to chemotherapy often develops.
  • In contrast to the successes obtained with pediatric patients, treatment outcomes for adults remain poor with only 40% of patients being long-term survivors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200049.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 136
  •  go-up   go-down


38. Kourti M, Vavatsi N, Gombakis N, Tzimagiorgis G, Sidi V, Koliouskas D, Athanassiadou F: Increased expression of multidrug resistance gene (MDR1) at relapse in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2006 Sep;23(6):489-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of multidrug resistance gene (MDR1) at relapse in a child with acute lymphoblastic leukemia.
  • Modern treatment protocols lead to complete remission in a high proportion of patients with childhood acute lymphoblastic leukemia (ALL).
  • Treatment failure in these patients is mainly attributable to de novo or acquired resistance to a wide variety of cytotoxic drugs, which is called multi drug resistance (MDR).
  • In order to contribute further information we present a rare case of a 15-month old girl with newly diagnosed CALLA positive pre-B acute lymphoblastic leukemia with favourable prognostic factors at diagnosis who experienced a relapse of the disease.
  • This is the first report on increased mRNA expression at relapse in a paired sample of a child with ALL in our region.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. P-Glycoprotein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Female. Humans. Infant. Neprilysin. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Messenger / analysis. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849280.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / RNA, Messenger; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


39. Reilly JJ: Energy balance and its measurement in childhood disease. Pediatr Blood Cancer; 2008 Feb;50(2 Suppl):452-5; discussion 468
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Energy balance and its measurement in childhood disease.
  • Under and overweight, usually secondary to energy imbalance, are common complications of childhood chronic disease.
  • In some diseases, such as acute lymphoblastic leukemia, the natural history and etiology of energy imbalance are now particularly well understood.
  • [MeSH-minor] Child. Chronic Disease. Disease. Humans. Thinness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18064640.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


40. Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M: Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia; 2006 Feb;20(2):254-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
  • Wilms' tumor gene 1 (WT1) is overexpressed in the majority (70-90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia.
  • We examined WT1 expression patterns in childhood acute lymphoblastic leukemia (ALL), where its clinical implication remains unclear.
  • Using a real-time quantitative PCR designed according to Europe Against Cancer Program recommendations, we evaluated WT1 expression in 125 consecutively enrolled patients with childhood ALL (106 BCP-ALL, 19 T-ALL) and compared it with physiologic WT1 expression in normal and regenerating bone marrow (BM).
  • In childhood B-cell precursor (BCP)-ALL, we detected a wide range of WT1 levels (5 logs) with a median WT1 expression close to that of normal BM.
  • WT1 expression in childhood T-ALL was significantly higher than in BCP-ALL (P<0.001).
  • In summary, our study suggests that WT1 expression in childhood ALL is very variable and much lower than in AML or adult ALL.
  • WT1, thus, will not be a useful marker for MRD detection in childhood ALL, however, it does represent a potential independent risk factor in childhood ALL.
  • Interestingly, a proportion of childhood ALL patients express WT1 at levels below the normal physiological BM WT1 expression, and this reduced WT1 expression appears to be associated with a higher risk of relapse.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Molecular Diagnostic Techniques / methods. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. WT1 Proteins / genetics
  • [MeSH-minor] Adolescent. Age Factors. Bone Marrow / metabolism. Child. Child, Preschool. Chromosome Aberrations. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Prognosis. Recurrence. Reverse Transcriptase Polymerase Chain Reaction / methods. Risk Factors. Survival Analysis


46. Simone JV: History of the treatment of childhood ALL: a paradigm for cancer cure. Best Pract Res Clin Haematol; 2006;19(2):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] History of the treatment of childhood ALL: a paradigm for cancer cure.
  • The history of the treatment of childhood leukemia from 1950 to the present is reviewed here.
  • Strengths and weaknesses in the current treatment of childhood leukemia are discussed as well as possibilities for the future.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Therapy / history. Drug Therapy / methods. Drug Therapy / trends. Female. History, 20th Century. History, 21st Century. Humans. Male. Radiotherapy / history. Radiotherapy / methods. Radiotherapy / trends. Survival Rate / trends

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516133.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 16
  •  go-up   go-down


47. Slats AM, Egeler RM, van der Does-van den Berg A, Korbijn C, Hählen K, Kamps WA, Veerman AJ, Zwaan CM: Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia; 2005 Apr;19(4):537-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience.
  • We analyzed causes of death, other than resistant disease or relapse, in 875 children with acute lymphoblastic leukemia (ALL) and 229 with acute myeloid leukemia (AML), treated on three different Dutch Childhood Oncology Group (DCOG) ALL and three AML protocols.
  • [MeSH-major] Leukemia, Myeloid / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Agents / adverse effects. Cause of Death. Child. Child, Preschool. Female. Humans. Infant. Male. Netherlands / epidemiology. Remission Induction


48. Hosking FJ, Papaemmanuil E, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Taylor M, Tomlinson IP, Greaves M, Houlston RS: Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk. Blood; 2010 Jun 3;115(22):4472-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk.
  • To examine whether homozygosity is associated with an increased risk of developing childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), we analyzed 824 ALL cases and 2398 controls genotyped for 292 200 tagging SNPs.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231427.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / 10417; United Kingdom / Cancer Research UK / / C1298/A8362
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Erythropoietin
  •  go-up   go-down


49. Rai SN, Hudson MM, McCammon E, Carbone L, Tylavsky F, Smith K, Surprise H, Shelso J, Pui CH, Kaste S: Implementing an intervention to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia: BONEII, a prospective placebo-controlled double-blind randomized interventional longitudinal study design. Contemp Clin Trials; 2008 Sep;29(5):711-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implementing an intervention to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia: BONEII, a prospective placebo-controlled double-blind randomized interventional longitudinal study design.
  • The baseline study (Study 1) aims to estimate the prevalence of diminished bone mineral density (BMD) in patients treated for childhood acute lymphoblastic leukemia (ALL) and identify risk factors for BMD deficits.
  • The extensive information being collected through this large study will serve as a repository of relational data about BMD and bone turnover and will support further investigations to assess the association of calcium metabolism, bone turnover, nutritional intake, lifestyle factors (such as exercise and the use of alcohol and tobacco), and the specific agents used in ALL therapy in this rapidly increasing population of childhood cancer survivors.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1999 Nov;33(5):455-61 [10531569.001]
  • [Cites] Pediatr Blood Cancer. 2008 May;50(5):1032-8 [17570705.001]
  • [Cites] J Bone Miner Res. 1999 Dec;14(12):2010-4 [10620059.001]
  • [Cites] Int J Clin Pract. 1998 Nov-Dec;52(8):557-65 [10622055.001]
  • [Cites] Stat Med. 2000 Jan 30;19(2):205-20 [10641025.001]
  • [Cites] Osteoporos Int. 2000;11(4):281-94 [10928217.001]
  • [Cites] Med Pediatr Oncol. 2000 Oct;35(4):415-20 [11025472.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Leukemia. 2001 May;15(5):728-34 [11368432.001]
  • [Cites] J Pediatr Endocrinol Metab. 2001 Jul-Aug;14(7):817-32 [11515724.001]
  • [Cites] J Pediatr. 2002 Aug;141(2):204-10 [12183715.001]
  • [Cites] J Pediatr Endocrinol Metab. 2003 Mar;16 Suppl 2:343-53 [12729414.001]
  • [Cites] Bone Marrow Transplant. 2004 Feb;33(4):435-41 [14716354.001]
  • [Cites] Pediatr Radiol. 2004 May;34(5):373-8; quiz 443-4 [14963622.001]
  • [Cites] Sports Med. 2005;35(9):779-830 [16138787.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):182-3; discussion 184 [15236291.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Chronic Dis. 1974 Sep;27(7-8):365-75 [4612056.001]
  • [Cites] Biometrics. 1989 Sep;45(3):939-55 [2486189.001]
  • [Cites] Lancet. 1991 Jan 12;337(8733):61-6 [1670723.001]
  • [Cites] JAMA. 1993 Aug 18;270(7):841-4 [8340983.001]
  • [Cites] Biometrics. 1997 Sep;53(3):937-47 [9290224.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 May-Jun;20(3):234-40 [9628435.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3174-81 [10487683.001]
  • [Cites] Int J Sports Med. 2005 Jun;26(5):332-8 [15895314.001]
  • [Cites] Am J Clin Nutr. 2005 Nov;82(5):1115-26; quiz 1147-8 [16280447.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jan;46(1):77-87 [16106430.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Calcif Tissue Int. 2006 Feb;78(2):65-71 [16467972.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(2):CD005119 [16625624.001]
  • [Cites] J Pediatr. 2006 Jun;148(6):793-9 [16769389.001]
  • [Cites] Genes Dev. 2006 Sep 15;20(18):2492-506 [16980579.001]
  • [Cites] BMJ. 2006 Oct 14;333(7572):775 [16980314.001]
  • [Cites] J Child Health Care. 2006 Dec;10(4):337-50 [17101625.001]
  • [Cites] Arch Pediatr Adolesc Med. 2006 Dec;160(12):1269-76 [17146025.001]
  • [Cites] J Bone Miner Res. 2007 Mar;22(3):458-64 [17181396.001]
  • [Cites] J Bone Miner Res. 2007 Mar;22(3):434-46 [17181400.001]
  • [Cites] Int J Sport Nutr Exerc Metab. 2006 Dec;16(6):580-96 [17342880.001]
  • [Cites] J Bone Miner Res. 2007 Apr;22(4):527-36 [17227221.001]
  • [Cites] J Phys Act Health. 2007 Jan;4(1):17-29 [17489004.001]
  • [Cites] J Bone Miner Res. 1999 Dec;14(12):2002-9 [10620058.001]
  • (PMID = 18586578.001).
  • [ISSN] 1559-2030
  • [Journal-full-title] Contemporary clinical trials
  • [ISO-abbreviation] Contemp Clin Trials
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA-21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / CA020180-209003; United States / NCI NIH HHS / CA / P01 CA020180; United States / NCI NIH HHS / CA / P01 CA020180-209003
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS69260; NLM/ PMC2613024
  •  go-up   go-down


50. Xiao PF, Chai YH, Li JQ, He HL, Wang Y, Li ZP, He YX, Ji ZH: [Therapeutic effectiveness of CCLG-97 protocol on standard-risk childhood acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2005 Jul;43(7):486-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic effectiveness of CCLG-97 protocol on standard-risk childhood acute lymphoblastic leukemia].
  • OBJECTIVE: With the improvement of the diagnosis and treatment, the complete remission (CR) rate and the survival rate of childhood acute lymphoblastic leukemia have been increased in the recent 10 years.
  • The objective of this study was to analyze the outcomes of 119 standard-risk childhood acute lymphoblastic leukemia (SR-ALL) patients, and explore how to improve the survival rate in ALL.
  • METHODS: A total of 119 patients aged 14 months to 15 years were diagnosed as SR-ALL according to the Suggestion of Diagnosis And Treatment for Childhood Acute Leukemia-1993.
  • CONCLUSION: Reinforcing administration and regular therapy are important to improve the long-term survival rate in childhood ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control
  • [MeSH-minor] Adolescent. Child. Child, Preschool. China. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Remission Induction / methods. Risk Factors. Secondary Prevention. Survival Rate. Time Factors. Treatment Outcome


51. Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, Sklar CA: Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Pediatr; 2007 Apr;150(4):370-5, 375.e1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.
  • OBJECTIVE: To determine risk factors associated with reduced adult height in survivors of childhood acute lymphoblastic leukemia (ALL).
  • Attained adult height was determined among 2434 ALL survivors participating in the Childhood Cancer Survivor Study, a cohort of 5-year survivors of common pediatric cancers diagnosed from 1970 to 1986, and compared with 3009 siblings.
  • CONCLUSIONS: Survivors of childhood ALL are at increased risk of adult short stature, including those treated with chemotherapy alone.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Adolesc Med. 2002 Feb;13(1):161-9, viii [11841962.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] Int J Cancer. 2001;96 Suppl:117-24 [11992395.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2953-60 [12885815.001]
  • [Cites] Med Pediatr Oncol. 1985;13(1):14-21 [3871501.001]
  • [Cites] Am J Dis Child. 1987 May;141(5):550-2 [3578168.001]
  • [Cites] Arch Dis Child. 1987 Nov;62(11):1107-12 [3479948.001]
  • [Cites] Lancet. 1988 Feb 27;1(8583):460-2 [2893877.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):400-5 [1999710.001]
  • [Cites] Arch Dis Child. 1991 Dec;66(12):1403-7 [1776886.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] Pediatr Res. 1993 Jun;33(6):577-82 [8378115.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):546-52 [8410505.001]
  • [Cites] Arch Dis Child. 1994 Jun;70(6):472-5 [8048814.001]
  • [Cites] Acta Paediatr. 1994 Dec;83(12):1287-90 [7734872.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 May;17(2):167-71 [7749768.001]
  • [Cites] Acta Paediatr. 1996 Sep;85(9):1091-5 [8888924.001]
  • [Cites] Acta Paediatr. 1996 Sep;85(9):1096-101 [8888925.001]
  • [Cites] J Pediatr. 1997 Oct;131(4):598-602 [9386666.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):351-6 [9589084.001]
  • [Cites] Eur J Pediatr. 1998 Sep;157(9):703-7 [9776525.001]
  • [Cites] Arch Dis Child. 1998 Aug;79(2):161-4 [9797600.001]
  • [Cites] Pediatr Blood Cancer. 2005 Aug;45(2):139-43 [15714445.001]
  • [Cites] Nutr J. 2005;4:27 [16209706.001]
  • [Cites] Am J Dis Child. 1988 Nov;142(11):1199-202 [3177326.001]
  • [CommentIn] J Pediatr. 2007 Apr;150(4):332-4 [17382105.001]
  • (PMID = 17382112.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA055727-11; United States / NCI NIH HHS / CA / CA055727-11; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / T32 CA009351; United States / NCI NIH HHS / CA / CA009351-27; United States / NCI NIH HHS / CA / U24-CA55727; United States / NCI NIH HHS / CA / T32 CA009351-27
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS21154; NLM/ PMC2766352
  •  go-up   go-down


52. Hunger SP, Loh KM, Baker KS, Schultz KR: Controversies of and unique issues in hematopoietic cell transplantation for infant leukemia. Biol Blood Marrow Transplant; 2009 Jan;15(1 Suppl):79-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies of and unique issues in hematopoietic cell transplantation for infant leukemia.
  • Infants with leukemia who require hematopoietic cell transplantation (HCT) remain 1 of the most significant challenges in pediatric stem cell transplant.
  • Infant leukemia is characterized by a unique biology including a predominance mixed lineage leukemia(MLL) gene rearrangement and juvenile myelomonocytic leukemia.
  • Currently, there is no solid basis to support allogeneic HCT as first-line therapy for infant acute lymphoblastic leukemia-first remission (ALL-CR1), although indicated for other infant leukemias, including juvenile myelomonocytic leukemia (JMML).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia / complications. Leukemia / therapy
  • [MeSH-minor] Humans. Infant. Infant, Newborn. Leukemia, Biphenotypic, Acute / complications. Leukemia, Biphenotypic, Acute / therapy. Leukemia, Myelomonocytic, Juvenile / complications. Leukemia, Myelomonocytic, Juvenile / therapy. Transplantation, Homologous. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147083.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Xu HG, Fang JP, Huang SL, Zhou DH, Chen C, Huang K, Li Y: [Risk factors and treatment of hemorrhagic cystitis in children after hematopoietic stem cell transplantation]. Zhonghua Er Ke Za Zhi; 2006 Feb;44(2):126-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From October 1998 to June the clinical records of 53 pediatric patients (aged 2-18 years with median age of 7.5 years) in our HCST center who underwent UCBT (n = 37) and PBSCT (n = 16) were retrospectively analyzed.
  • Thirty out of 53 patients were diagnosed as hereditary hemolytic anemia (56.6%), and the others as haematological malignancies (43.4%): of whom 8 had acute lymphoblastic leukemia, 12 acute myeloid leukemia, 2 chronic myeloid leukemia and 1 non-hodgkin lymphoma.
  • Total body irradiation (TBI) or total lymphoid irradiation was added in 7 patients respectively.
  • [MeSH-minor] Adolescent. Age Factors. Body Water / metabolism. Child. Child, Preschool. Female. Fluid Therapy / methods. Humans. Incidence. Male. Mesna / therapeutic use. Multivariate Analysis. Protective Agents / therapeutic use. Retrospective Studies. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624030.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protective Agents; NR7O1405Q9 / Mesna
  •  go-up   go-down


54. Geenen MM, Bakker PJ, Kremer LC, Kastelein JJ, van Leeuwen FE: Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy. Pediatr Blood Cancer; 2010 Oct;55(4):690-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy.
  • BACKGROUND: Only a few studies have assessed cardiovascular risk factors (CRFs) in childhood cancer survivors.
  • We determined the prevalence of CRFs in long-term survivors of acute lymphoblastic leukemia (ALL) and Wilms tumor.
  • [MeSH-major] Cardiovascular Diseases / etiology. Kidney Neoplasms / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Wilms Tumor / complications
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Infant. Infant, Newborn. Lipids / blood. Prevalence. Risk Factors. Survivors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • (PMID = 20589650.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


55. Rimmer RB, Weigand S, Foster KN, Wadsworth MM, Jacober K, Matthews MR, Drachman D, Caruso DM: Scald burns in young children--a review of Arizona burn center pediatric patients and a proposal for prevention in the Hispanic community. J Burn Care Res; 2008 Jul-Aug;29(4):595-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scald burns in young children--a review of Arizona burn center pediatric patients and a proposal for prevention in the Hispanic community.
  • Arizona Burn Center staff observed an increasing number of pediatric scald burn admissions.
  • Arizona Burn Center scald admission variables (ages 0-5 years) reviewed included age, sex, ethnicity, TBSA, body parts burned, occurrence month and location, caregiver present, child and caregiver activities when injured, payor source, length of stay, parental language, and zip code.
  • There were a total of 170 pediatric patients, aged 0 to 5 years, admitted to the burn center during 2005 to 2006.
  • Of this total, 124 of the patients were admitted for scald burns, accounting for 59% of all pediatric burn admissions.
  • The remaining pediatric admissions for children aged 0 to 5 were for burns caused by fire or flame 15%, contact with a hot object 13%, friction burns 7%, chemical burns 3%, and electrical burns 3%.
  • Most common child behaviors were pulling hot substance from stove (24%), from countertop (13%), and having liquid spilled on them (13%) typically while caregiver was cooking.
  • Scalds occurred in the kitchen (83%) and mainly in child's home (94%).
  • Results suggest that culturally sensitive, bilingual scald prevention education, targeting Hispanics, is needed to create awareness of the frequency, severity, and danger associated with pediatric scalds.
  • [MeSH-minor] Accidents, Home / statistics & numerical data. Arizona / epidemiology. Burn Units. Child, Preschool. Cooking. Female. Focus Groups. Health Education. Humans. Infant. Infant, Newborn. Injury Severity Score. Length of Stay / statistics & numerical data. Male. Patient Admission / statistics & numerical data. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18535476.001).
  • [ISSN] 1559-047X
  • [Journal-full-title] Journal of burn care & research : official publication of the American Burn Association
  • [ISO-abbreviation] J Burn Care Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B, Rebbeck T: Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res; 2005 Mar 15;65(6):2482-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia.
  • A significant portion of patients treated for pediatric acute lymphoblastic leukemia (ALL) relapse.
  • Methotrexate (MTX), which interrupts folate metabolism, is a mainstay of pediatric ALL therapy.
  • These data provide evidence that the MTHFR C677T polymorphism is a common genetic variant conferring a moderate relative risk and a high attributable risk for relapse in pediatric ALL patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Methotrexate / therapeutic use. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • [MeSH-minor] Alleles. Case-Control Studies. Child, Preschool. Female. Humans. Male. Polymorphism, Genetic


57. Torelli GF, Guarini A, Maggio R, Alfieri C, Vitale A, Foà R: Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. Haematologica; 2005 Jun;90(6):785-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
  • The anti-leukemic activity of NK cells against acute myeloid leukemia (AML) blasts has been described, but very few data are available for acute lymphoid leukemia (ALL).
  • The present study was designed to investigate whether: (i) NK effectors could be expanded from adult and pediatric ALL patients in complete remission;.
  • (v) any differences in cytotoxic activity could be found between expanded effectors from adult and pediatric patients.
  • No differences in expansion and cytotoxic activity were found between pediatric and adult patients.
  • [MeSH-major] Immunotherapy / methods. Killer Cells, Natural / cytology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Child. Coculture Techniques. Cytokines / metabolism. Flow Cytometry. Humans. Interleukin-15 / metabolism. Interleukin-2 / metabolism. Receptors, IgG / metabolism. Remission Induction. Signal Transduction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951291.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-15; 0 / Interleukin-2; 0 / Receptors, IgG
  •  go-up   go-down


58. Gümüş H, Per H, Kumandaş S, Yikilmaz A: Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature. Neurol Sci; 2010 Apr;31(2):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature.
  • We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.
  • Early recognition of RPLS as complication during different diseases and therapy in childhood may facilitate precise diagnosis and appropriate treatment.
  • [MeSH-minor] Adolescent. Brain / pathology. Child. Diagnosis, Differential. Early Diagnosis. Female. Humans. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Aug;21(7):1199-206 [10954269.001]
  • [Cites] J Neurol. 2002 Jun;249(6):780-1 [12173578.001]
  • [Cites] Neurology. 1999 Apr 12;52(6):1285-8 [10214762.001]
  • [Cites] Epilepsia. 1998 Mar;39(3):295-9 [9578048.001]
  • [Cites] Stroke. 1997 May;28(5):1082-5 [9158653.001]
  • [Cites] Pediatr Radiol. 2005 Jul;35(7):722-7 [15756541.001]
  • [Cites] Pediatr Nephrol. 2001 Jul;16(7):601-3 [11465812.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):591 [9541327.001]
  • [Cites] Radiology. 2001 Jun;219(3):756-65 [11376265.001]
  • [Cites] Arch Gynecol Obstet. 2005 Jan;271(1):79-85 [15480723.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):1038-48 [12063238.001]
  • [Cites] Pediatr Neurol. 1999 Mar;20(3):241-3 [10207937.001]
  • [Cites] Pediatr Neurol. 2006 Mar;34(3):245-7 [16504799.001]
  • [Cites] Eur J Neurol. 2006 Mar;13(3):309-10 [16618354.001]
  • [Cites] Ann Intern Med. 1995 Oct 15;123(8):598-600 [7677301.001]
  • [Cites] Intern Med J. 2005 Feb;35(2):83-90 [15705136.001]
  • [Cites] Nephrol Dial Transplant. 1989;4(12):1065-9 [2517327.001]
  • [Cites] AJR Am J Roentgenol. 1992 Aug;159(2):379-83 [1632361.001]
  • [Cites] Pediatr Infect Dis J. 2006 Jan;25(1):85-7 [16395114.001]
  • [Cites] Curr Opin Pediatr. 1999 Dec;11(6):512-8 [10590909.001]
  • [Cites] Radiology. 1991 Aug;180(2):475-8 [2068315.001]
  • [Cites] Eur J Pediatr. 2004 Dec;163(12):728-30 [15322868.001]
  • [Cites] Pediatr Neurol. 2001 May;24(5):361-4 [11516610.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):198-203 [16123992.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Jun-Jul;16(6):1344-6 [7677037.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):447-55 [18079186.001]
  • [Cites] Radiology. 2000 Nov;217(2):371-6 [11058630.001]
  • [Cites] Pediatr Nephrol. 2003 Nov;18(11):1161-6 [14505162.001]
  • [Cites] Pediatr Nephrol. 1993 Apr;7(2):194-5 [8476718.001]
  • [Cites] Neurology. 2001 Feb 13;56(3):388-91 [11171907.001]
  • [Cites] Neurology. 1998 Nov;51(5):1369-76 [9818862.001]
  • [Cites] J Comput Assist Tomogr. 2007 Jan-Feb;31(1):148-56 [17259848.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):494-500 [8559202.001]
  • [Cites] Clin Neurol Neurosurg. 1997 Aug;99(3):222-6 [9350407.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jan;18(1):101-6 [9010526.001]
  • [Cites] Postgrad Med J. 2001 Jan;77(903):24-8 [11123390.001]
  • [Cites] Blood. 2003 Jan 15;101(2):415-9 [12393443.001]
  • [Cites] Neurology. 1997 Oct;49(4):1174-5 [9339716.001]
  • [Cites] BMJ. 1989 Nov 18;299(6710):1258-9 [2513901.001]
  • (PMID = 19809787.001).
  • [ISSN] 1590-3478
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 42
  •  go-up   go-down


59. Gustafsson B, Angelini S, Sander B, Christensson B, Hemminki K, Kumar R: Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia; 2005 Feb;19(2):310-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia.
  • [MeSH-major] Genes, ras. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins B-raf / genetics
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation. Child. Child, Preschool. Exons. Female. Humans. Infant. Male. Mutation

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2008 Aug;22(8):1619-21 [18273045.001]
  • (PMID = 15538400.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


60. Hammer LD, Curry ES, Harlor AD, Laughlin JJ, Leeds AJ, Lessin HR, Rodgers CT, Granado-Villar DC, Brown JM, Cotton WH, Gaines BM, Gambon TB, Gitterman BA, Gorski PA, Kraft CA, Marino RV, Paz-Soldan GJ, Zind B, Committee on Practice and Ambulatory Medicine, Council on Community Pediatrics: Increasing immunization coverage. Pediatrics; 2010 Jun;125(6):1295-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data from the 2007 National Immunization Survey showed that 90% of children 19 to 35 months of age have received recommended doses of each of the following vaccines: inactivated poliovirus (IPV), measles-mumps-rubella (MMR), varicella-zoster virus (VZB), hepatitis B virus (HBV), and Haemophilus influenzae type b (Hib).
  • These challenges include an increase in new vaccines and new vaccine combinations as well as a significant number of vaccines currently under development; a dramatic increase in the acquisition cost of vaccines, coupled with a lack of adequate payment to practitioners to buy and administer vaccines; unanticipated manufacturing and delivery problems that have caused significant shortages of various vaccine products; and the rise of a public antivaccination movement that uses the Internet as well as standard media outlets to advance a position, wholly unsupported by any scientific evidence, linking vaccines with various childhood conditions, particularly autism.
  • Pediatricians should work individually and collectively at the local, state, and national levels to ensure that all children without a valid contraindication receive all childhood immunizations on time.
  • Pediatricians and pediatric organizations, in conjunction with government agencies such as the Centers for Disease Control and Prevention, must communicate effectively with parents to maximize their understanding of the overall safety and efficacy of vaccines.
  • [MeSH-minor] Child. Financing, Government / economics. Financing, Government / statistics & numerical data. Health Services Accessibility / economics. Healthy People Programs / standards. Humans. Immunization Schedule. Insurance Coverage. Practice Management, Medical / organization & administration. Public Sector / economics. Vaccines / economics


61. Lam WA, Rosenbluth MJ, Fletcher DA: Chemotherapy exposure increases leukemia cell stiffness. Blood; 2007 Apr 15;109(8):3505-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy exposure increases leukemia cell stiffness.
  • Here we report the effect of chemotherapy on leukemia cell mechanical properties.
  • Acute lymphoblastic and acute myeloid leukemia cells were incubated with standard induction chemotherapy, and individual cell stiffness was tracked with atomic force microscopy.
  • When exposed to dexamethasone or daunorubicin, leukemia cell stiffness increased by nearly 2 orders of magnitude, which decreased their passage through microfluidic channels.
  • This stiffness increase occurred before caspase activation and peaked after completion of cell death, and the rate of stiffness increase depended on chemotherapy type.
  • These observations suggest that chemotherapy itself may increase the risk of vascular complications in acute leukemia.
  • [MeSH-major] Daunorubicin / pharmacology. Dexamethasone / pharmacology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 2003 Oct 15;66(8):1611-7 [14555241.001]
  • [Cites] Ther Apher. 2002 Feb;6(1):15-23 [11886572.001]
  • [Cites] Arch Intern Med. 1972 Nov;130(5):759-62 [4507847.001]
  • [Cites] Blood. 1982 Aug;60(2):279-83 [7046844.001]
  • [Cites] Cancer. 1983 May 15;51(10):1808-13 [6831346.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):202-7 [3806166.001]
  • [Cites] Cancer Chemother Pharmacol. 1987;20(4):305-10 [3480081.001]
  • [Cites] Science. 1989 Jul 14;245(4914):183-6 [2749255.001]
  • [Cites] Science. 1995 May 26;268(5214):1142-3 [7539154.001]
  • [Cites] Am J Physiol. 1996 Dec;271(6 Pt 1):C1981-92 [8997201.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):368-74 [10023704.001]
  • [Cites] Microcirculation. 2005 Jan-Feb;12(1):5-15 [15804970.001]
  • [Cites] Langmuir. 2005 Sep 27;21(20):9280-6 [16171363.001]
  • [Cites] Neoplasma. 2006;53(1):56-61 [16416014.001]
  • [Cites] Biophys J. 2006 Apr 15;90(8):2994-3003 [16443660.001]
  • [Cites] Electrophoresis. 2000 Jan;21(1):27-40 [10634468.001]
  • [Cites] Cell Physiol Biochem. 2000;10(5-6):417-28 [11125224.001]
  • [Cites] Acta Histochem. 2001 Oct;103(4):453-64 [11700950.001]
  • [Cites] Oncol Rep. 2004 Apr;11(4):765-70 [15010870.001]
  • (PMID = 17179225.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 7S5I7G3JQL / Dexamethasone; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ PMC1852256
  •  go-up   go-down


62. Maruyama T, Yamamoto S, Nojima M, Morita N, Tanizawa T, Shima H: Extramedullary relapse of acute lymphoblastic leukemia in childhood to the prostate. Int J Urol; 2007 May;14(5):447-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary relapse of acute lymphoblastic leukemia in childhood to the prostate.
  • He had a past history of acute lymphoblastic leukemia (ALL), which subsided in response to chemotherapy at 3 years of age.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Child. Humans. Male. Recurrence


63. Stam RW, den Boer ML, Passier MM, Janka-Schaub GE, Sallan SE, Armstrong SA, Pieters R: Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia; 2006 Feb;20(2):264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
  • MLL rearranged acute lymphoblastic leukemia (MLL) is an aggressive type of acute lymphoblastic leukemia (ALL), diagnosed predominantly in infants (<1 years of age).
  • Likewise and more specifically, leukemic cell death was induced by transfecting MLL rearranged leukemic cells with expression vectors encoding wild-type FHIT, confirming tumor suppressor activity of this gene.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Gene Silencing. Myeloid-Lymphoid Leukemia Protein / genetics. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357833.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / fragile histidine triad protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


64. Bourquin JP, Izraeli S: Where can biology of childhood ALL be attacked by new compounds? Cancer Treat Rev; 2010 Jun;36(4):298-306
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Where can biology of childhood ALL be attacked by new compounds?
  • Although the majority of children with acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy, the challenge remains to salvage patients with resistant disease and to reduce treatment related toxicity.
  • Here we review the principles of current ALL therapy, recent advances in understanding ALL biology and discuss a selection of promising areas for drug development that may take advantage of the underlying leukemia biology.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Cell Differentiation / drug effects. Cell Survival / drug effects. Child. Drug Resistance, Neoplasm. Humans. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Protein-Serine-Threonine Kinases / antagonists & inhibitors. TOR Serine-Threonine Kinases

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20223597.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Number-of-references] 146
  •  go-up   go-down


65. Hamouda F, El-Sissy AH, Radwan AK, Hussein H, Gadallah FH, Al-Sharkawy N, Sedhom E, Ebeid E, Salem SI: Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia; experience at the National Cancer Institute, Cairo University, Egypt. J Egypt Natl Canc Inst; 2007 Jun;19(2):87-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia; experience at the National Cancer Institute, Cairo University, Egypt.
  • [MeSH-major] Antigens, Neoplasm / analysis. Immunophenotyping / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Case-Control Studies. Child. Chromosome Banding. Diploidy. Egypt. Female. Flow Cytometry. Follow-Up Studies. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Prognosis. Retrospective Studies. Universities


66. Jotta PY, Ganazza MA, Silva A, Viana MB, da Silva MJ, Zambaldi LJ, Barata JT, Brandalise SR, Yunes JA: Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia; 2010 Jan;24(1):239-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia.
  • [MeSH-major] Mutation. PTEN Phosphohydrolase / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Exons. Humans. Phosphatidylinositol 3-Kinases / physiology. Prognosis. Proto-Oncogene Proteins c-akt / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19829307.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


67. Mandrell BN: The genetic profile and monitoring of acute lymphoblastic leukemia in children and adolescents. J Pediatr Nurs; 2009 Jun;24(3):173-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The genetic profile and monitoring of acute lymphoblastic leukemia in children and adolescents.
  • The event-free survival rates of children diagnosed with acute lymphoblastic leukemia (ALL) demonstrate the advances that have been made in pediatric oncology and, more specifically, the improved understanding of the disease's heterogeneous characteristics.
  • Understanding of the heterogeneity, differences between ALL cases, has been propelled through genetic classification of the leukemia, molecular monitoring of treatment response based on the genetic classification of the leukemia, and an understanding of the individual patient's variability in response to treatment.
  • It is the culmination of the genetic profile of the leukemia, the individual patient, and molecular monitoring that has led to the earlier identification of patients who respond less favorably to treatment and thus prompts their treatment intensification and improved outcomes.
  • It is imperative that nurses become knowledgeable of leukemic genetic markers and molecular monitoring and their clinical significance when caring for the child and their family.
  • [MeSH-major] Cytogenetic Analysis / methods. Genomics / methods. Pediatric Nursing / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adolescent. Bone Marrow Examination. Child. Child, Preschool. Drug Monitoring. Humans. Leukocyte Count. Male. Polymorphism, Genetic / genetics. Prognosis. Risk Assessment. Risk Factors. Translocation, Genetic / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467429.001).
  • [ISSN] 1532-8449
  • [Journal-full-title] Journal of pediatric nursing
  • [ISO-abbreviation] J Pediatr Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


68. Attarbaschi A, Mann G, König M, Steiner M, Dworzak MN, Gadner H, Haas OA, Austrian Berlin-Frankfurt-Münster Cooperative Study Group: Near-tetraploidy in childhood B-cell precursor acute lymphoblastic leukemia is a highly specific feature of ETV6/RUNX1-positive leukemic cases. Genes Chromosomes Cancer; 2006 Jun;45(6):608-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Near-tetraploidy in childhood B-cell precursor acute lymphoblastic leukemia is a highly specific feature of ETV6/RUNX1-positive leukemic cases.
  • Near-tetraploidy (82-94 chromosomes) makes up fewer than 1% of childhood acute lymphoblastic leukemia (ALL) cases and has been reportedly associated with a possibly poorer prognosis compared with other ploidy groups.
  • Fluorescence in situ hybridization revealed that eight of the nine B-cell precursor (BCP) cases and none of the three T-cell ALL cases had an ETV6/RUNX1 rearrangement.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / analysis. Polyploidy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / analysis. Repressor Proteins / analysis
  • [MeSH-minor] Adolescent. Austria. Child. Child, Preschool. Cytogenetic Analysis. Humans. In Situ Hybridization, Fluorescence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Genetic Alliance. consumer health - Tetraploidy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16552772.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


69. Vergara Domínguez B, Cedré Hernández T, Martínez Cárdenas L, López García C, González Seivane F, Pichs León V, Alegret Martínez M, Pérez García S, Courell Martin G, Castro Martínez ME: [Outcome of acute lymphoblastic leukemia in the pediatric age group over a 29-year period (1972-2000)]. An Pediatr (Barc); 2006 Jan;64(1):52-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Outcome of acute lymphoblastic leukemia in the pediatric age group over a 29-year period (1972-2000)].
  • [Transliterated title] Evolución de la leucemia linfoblástica aguda en la edad pediátrica en 29 años (1972-2000).
  • OBJECTIVE: To evaluate the progress achieved in the treatment of acute lymphoblastic leukemia (ALL) in our hospital.
  • Group 2 was treated with less aggressive classical regimens from the 1970s, and groups 3 and 4 received more aggressive regimens, type Berlin-Frankfurt-Munster (BFM).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Humans. Infant. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16539917.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


70. Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, Evans WE, Pieters R, Den Boer ML: Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood; 2009 Feb 26;113(9):2014-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.
  • Treatment failure in pediatric acute lymphoblastic leukemia (ALL) is related to cellular resistance to glucocorticoids (eg, prednisolone).
  • Recently, we demonstrated that genes associated with glucose metabolism are differentially expressed between prednisolone-sensitive and prednisolone-resistant precursor B-lineage leukemic patients.
  • [MeSH-major] Drug Resistance, Neoplasm. Glycolysis / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1994 Dec;70(6):1047-52 [7981053.001]
  • [Cites] Future Oncol. 2007 Dec;3(6):655-64 [18041918.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2959-65 [9108416.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 Jan;25(1):11-26 [9134309.001]
  • [Cites] Anticancer Drugs. 1997 Jun;8(5):509-16 [9215615.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Blood. 1998 Jul 1;92(1):259-66 [9639525.001]
  • [Cites] Diabetes. 1998 Jul;47(7):1006-13 [9648821.001]
  • [Cites] Biochem Pharmacol. 1998 Oct 1;56(7):841-9 [9774146.001]
  • [Cites] Breast Cancer Res Treat. 1998 Jun;49(3):209-17 [9776504.001]
  • [Cites] J Biol Chem. 1999 Jul 16;274(29):20281-6 [10400647.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):613-21 [15695406.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):153-60 [15860257.001]
  • [Cites] J Pathol. 2005 Jul;206(3):291-304 [15906272.001]
  • [Cites] Strahlenther Onkol. 2005 Aug;181(8):507-14 [16044218.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1279-81 [16154856.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7435-42 [16288290.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Life Sci. 2006 Feb 16;78(12):1392-9 [16111712.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1045-9 [16574952.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4633-46 [16892078.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4683-96 [16892082.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8927-30 [16982728.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1731-7 [17041637.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]
  • [Cites] Mol Biol Cell. 2007 Apr;18(4):1437-46 [17301289.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3364-70 [17409446.001]
  • [Cites] Cancer Lett. 2007 Jun 8;250(2):300-10 [17125916.001]
  • [Cites] Cell Metab. 2008 Jan;7(1):11-20 [18177721.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2101-11 [18042802.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21797-800 [10823814.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):9519-25 [11120745.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(15):5575-84 [12101249.001]
  • [Cites] Mol Biol Cell. 2002 Jul;13(7):2276-88 [12134068.001]
  • [Cites] Leukemia. 2003 Jan;17(1):17-25 [12529655.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):919-29 [12648060.001]
  • [Cites] J Neurooncol. 2003 May;63(1):81-6 [12814259.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1358-66 [17499003.001]
  • [Cites] Chemotherapy. 2007;53(4):233-56 [17595539.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33384-91 [12810720.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] Cell Death Differ. 2004 Feb;11(2):165-74 [14576768.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):31-4 [14729604.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3892-9 [15172999.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 5;324(1):269-75 [15465013.001]
  • [Cites] Clin Exp Immunol. 1977 Apr;28(1):1-18 [324671.001]
  • [Cites] J Natl Cancer Inst. 1981 Mar;66(3):497-9 [6937706.001]
  • [Cites] Anal Biochem. 1987 Mar;161(2):508-13 [3555157.001]
  • [Cites] Blood. 1990 Dec 1;76(11):2327-36 [2257305.001]
  • [Cites] J Biol Chem. 1994 Sep 23;269(38):23757-63 [8089148.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):108-13 [17692803.001]
  • [Cites] J Bioenerg Biomembr. 2007 Jun;39(3):267-74 [17551814.001]
  • [Cites] Cell Signal. 2008 Jan;20(1):21-30 [17716864.001]
  • [Cites] Eur J Biochem. 1996 Oct 15;241(2):403-10 [8917436.001]
  • (PMID = 18978206.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Glucocorticoids; 5J49Q6B70F / Vincristine; 9G2MP84A8W / Deoxyglucose; 9PHQ9Y1OLM / Prednisolone; IY9XDZ35W2 / Glucose; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ PMC4081395
  •  go-up   go-down


71. Conklin HM, Khan RB, Reddick WE, Helton S, Brown R, Howard SC, Bonner M, Christensen R, Wu S, Xiong X, Mulhern RK: Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial. J Pediatr Psychol; 2007 Oct;32(9):1127-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial.
  • OBJECTIVE: To investigate the acute efficacy and adverse side effects of methylphenidate (MPH) among survivors of childhood cancer [acute lymphoblastic leukemia (ALL) or brain tumor (BT)] with learning impairments.
  • [MeSH-minor] Child. Child, Preschool. Cross-Over Studies. Double-Blind Method. Female. Humans. Male. Survival Rate. Wechsler Scales


72. Fangusaro J: Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J Child Neurol; 2009 Nov;24(11):1409-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas.
  • Pediatric high-grade gliomas represent approximately 10% of all pediatric brain tumors.
  • In this review, we present an overview of both pediatric high-grade gliomas and diffuse intrinsic pontine gliomas with a focus on their epidemiology, etiology, presentation, prognostic factors, biology, treatment modalities, outcomes, and future research directions.
  • [MeSH-minor] Child. Humans. Models, Neurological. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638636.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 83
  •  go-up   go-down


73. Harned TM, Gaynon P: Relapsed acute lymphoblastic leukemia: current status and future opportunities. Curr Oncol Rep; 2008 Nov;10(6):453-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsed acute lymphoblastic leukemia: current status and future opportunities.
  • Significant improvements in primary therapy for childhood acute lymphoblastic leukemia (ALL) have led to dramatic increases in cure rates over the past few decades.
  • Relapsed ALL, however, remains more common than new diagnoses of many common pediatric malignancies.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Child. Clinical Trials as Topic. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Medical Oncology / methods. Prognosis. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Pharmacother. 2005 Jun;39(6):1056-63 [15870141.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2826-32 [17099879.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Blood. 2005 Feb 1;105(3):940-7 [15486072.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2321-32 [9404710.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;4(5):369-70 [15902772.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):1-2 [17325839.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1043-50 [17640858.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2057-66 [17536015.001]
  • [Cites] Med Pediatr Oncol. 1998 Apr;30(4):233-9 [9473758.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5800-7 [18089878.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):361-8 [15723262.001]
  • [Cites] Leukemia. 2003 Oct;17(10):1967-72 [14513046.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):13-23 [16292537.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53 [17069520.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):68-72 [9065722.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1331-41 [16814387.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4961-7 [16493003.001]
  • [Cites] Bone Marrow Transplant. 2008 Jan;41(2):133-9 [17994118.001]
  • [Cites] Leukemia. 2008 Feb;22(2):281-6 [18033318.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):24-9 [12823342.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • (PMID = 18928659.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 44
  •  go-up   go-down


74. Van Vlierberghe P, Beverloo HB, Buijs-Gladdines J, van Wering ER, Horstmann M, Pieters R, Meijerink JP: Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia. Leukemia; 2008 Jul;22(7):1434-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia.
  • [MeSH-major] Alleles. DNA-Binding Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Metalloproteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Child, Preschool. Gene Deletion. Humans. In Situ Hybridization, Fluorescence. LIM Domain Proteins. Nucleic Acid Amplification Techniques. Proto-Oncogene Proteins

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079736.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


75. Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altomare M, Perutelli P, Crescenzio N, Santoro N, Marchetti M, De Mattia D, Falanga A: Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. Am J Hematol; 2010 May;85(5):325-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.
  • In a group of newly diagnosed acute lymphocytic leukemia (ALL) children we evaluated a number of hemostatic and inflammatory markers at diagnosis and at different time points during chemotherapy for the remission induction to identify alterations in the plasma levels of prothrombotic markers before and during the course of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thrombophilia / chemically induced. Thrombophilia / physiopathology
  • [MeSH-minor] 6-Mercaptopurine / adverse effects. Adolescent. Antithrombins / metabolism. Asparaginase / adverse effects. Case-Control Studies. Child. Child, Preschool. Cyclophosphamide / adverse effects. Cytarabine / adverse effects. Daunorubicin / adverse effects. Female. Fibrin Fibrinogen Degradation Products / metabolism. Humans. Infant. Longitudinal Studies. Male. Methotrexate / adverse effects. P-Selectin / blood. Plasminogen Activator Inhibitor 1 / blood. Prednisone / adverse effects. Prospective Studies. Risk Factors. Thrombin / metabolism. Venous Thromboembolism / chemically induced. Vincristine / adverse effects. von Willebrand Factor / immunology. von Willebrand Factor / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20425794.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antithrombins; 0 / Fibrin Fibrinogen Degradation Products; 0 / P-Selectin; 0 / Plasminogen Activator Inhibitor 1; 0 / SERPINE1 protein, human; 0 / Von Willebrand antigen; 0 / fibrin fragment D; 0 / von Willebrand Factor; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.4.21.5 / Thrombin; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


76. Lee AC, Wong LG: Facial palsy, corticosteroids, and acute leukemia. Pediatr Neurol; 2007 Feb;36(2):137; author reply 137-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Facial palsy, corticosteroids, and acute leukemia.
  • [MeSH-major] Adrenal Cortex Hormones / contraindications. Facial Paralysis / drug therapy. Facial Paralysis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Neurol. 2006 Jun;34(6):502-4 [16765834.001]
  • (PMID = 17275671.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


77. Nygren MK, Døsen-Dahl G, Stubberud H, Wälchli S, Munthe E, Rian E: beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells. Exp Hematol; 2009 Feb;37(2):225-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells.
  • OBJECTIVE: The t(1;19)(q23;13) translocation, resulting in the production of the E2A-PBX1 chimeric protein, is a common nonrandom translocation in pediatric B-lineage acute lymphoblastic leukemia (B-ALL).
  • Localization of beta-catenin in the cell membrane and its involvement in leukemia-stroma interaction were studied by confocal microscopy.
  • E2A-PBX1-positive leukemia cells adhered strongly to bone marrow stroma cells, and we showed that adherence junctions stained strongly for both proteins.
  • Moreover, knockdown of beta-catenin reduced the adhesion of E2A-PBX1-positive leukemia cells to N-cadherin, suggesting that beta-catenin and N-cadherin play a central role in homotypic cell-to-cell adhesion and in leukemia-stroma adhesion.
  • Instead, beta-catenin is involved in N-cadherin-dependent adherence junctions, suggesting for the first time that leukemia-stroma interactions may be mediated via an N-cadherin-dependent mechanism.
  • [MeSH-major] Cadherins / metabolism. Homeodomain Proteins / metabolism. Leukemia, B-Cell / metabolism. Oncogene Proteins, Fusion / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Signal Transduction. Wnt Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adherens Junctions / genetics. Adherens Junctions / metabolism. Cell Adhesion / genetics. Cell Line, Tumor. Child. Child, Preschool. Chromosomes, Human / genetics. Chromosomes, Human / metabolism. Humans. Translocation, Genetic / genetics


78. Djokic M, Björklund E, Blennow E, Mazur J, Söderhäll S, Porwit A: Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica; 2009 Jul;94(7):1016-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia.
  • We evaluated CD123 expression in 95 pediatric and 24 adult ALL patients and compared the results with the CD123 expression in normal B-cell precursors.
  • Leukemic blasts in 31% of precursor-B ALL samples exhibited strong expression of CD123, 61% had moderate CD123 expression and 8% were negative; 81.5% of ALL with hyperdiploid karyotype (>/= 52 chromosomes) showed strong CD123 overexpression.
  • Our study suggests that overexpression of CD123 is an aberrant phenotype present in a subset of precursor-B ALL with hyperdiploid genotype, and represents an additional marker of good prognosis in pediatric precursor-B ALL.
  • [MeSH-major] Diploidy. Gene Expression Regulation, Leukemic. Interleukin-3 Receptor alpha Subunit / biosynthesis. Interleukin-3 Receptor alpha Subunit / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Genotype. Humans. Infant. Infant, Newborn. Karyotyping. Middle Aged. Phenotype

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Mar;14(3):403-11 [10720134.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1908-10 [16900212.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4634-7 [12036900.001]
  • [Cites] Leukemia. 2003 Jan;17(1):138-48 [12529671.001]
  • [Cites] Leukemia. 2004 Feb;18(2):219-26 [14671644.001]
  • [Cites] Blood. 1989 Feb;73(2):533-42 [2644978.001]
  • [Cites] Annu Rev Immunol. 1992;10:295-331 [1590989.001]
  • [Cites] Blood. 1993 Jul 1;82(1):22-8 [8100720.001]
  • [Cites] Blood. 1996 Jan 1;87(1):112-22 [8547632.001]
  • [Cites] Leukemia. 1999 Mar;13(3):419-27 [10086733.001]
  • [Cites] Med Pediatr Oncol. 1999 May;32(5):360-5 [10219338.001]
  • [Cites] Leukemia. 1999 Aug;13(8):1109-66 [10450743.001]
  • [Cites] Leukemia. 2005 Jan;19(1):49-56 [15538405.001]
  • [Cites] Immunol Lett. 2005 Apr 15;98(1):9-21 [15790504.001]
  • [Cites] Eur J Haematol. 2005 Jun;74(6):466-80 [15876250.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2527-9 [15928038.001]
  • [Cites] Haematologica. 2001 Dec;86(12):1261-9 [11726317.001]
  • (PMID = 19454491.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Interleukin-3 Receptor alpha Subunit
  • [Other-IDs] NLM/ PMC2704314
  •  go-up   go-down


79. Tumer TB, Yilmaz D, Tanrikut C, Sahin G, Ulusoy G, Arinç E: DNA repair XRCC1 Arg399Gln polymorphism alone, and in combination with CYP2E1 polymorphisms significantly contribute to the risk of development of childhood acute lymphoblastic leukemia. Leuk Res; 2010 Oct;34(10):1275-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA repair XRCC1 Arg399Gln polymorphism alone, and in combination with CYP2E1 polymorphisms significantly contribute to the risk of development of childhood acute lymphoblastic leukemia.
  • In this study, we investigated the possible association of X-ray repair cross-complimenting group 1 (XRCC1) Arg399Gln and Arg194Trp variants with the risk of incidence of childhood acute lymphoblastic leukemia (ALL) in Turkish population comprised of 190 healthy controls and 167 ALL patients.
  • In case of codon 194 polymorphism, no significant associations have been found with risk of childhood ALL.
  • In addition, none of the combinations of XRCC1 codon 194 and 399 polymorphisms have been found to be significantly associated with childhood ALL risk.
  • In the scope of this study, we have also showed that the co-presence of XRCC1 codon 399 and CYP2E1*5B and *6 polymorphisms (data for CYP2E1 polymorphisms drawn from previously published study conducted in our lab) in the same individuals considerably increased the risk for childhood ALL to 3.7-fold with borderline significance (p=0.049).
  • This is the first study showing combined associations of XRCC1 399Gln, CYP2E1*5B and *6 alleles with the risk of development of childhood ALL.
  • [MeSH-major] Cytochrome P-450 CYP2E1 / genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. DNA Damage. DNA Repair. Female. Humans. Infant. Male. Risk

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20394984.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; EC 1.14.13.- / Cytochrome P-450 CYP2E1
  •  go-up   go-down


80. Tie LJ, Gu LJ, Jiang LM, Zhao JC, Chen J, Pan C, Dong L, Chen J, Xue HL, Tang JY, Wang YP: [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr;11(4):246-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia].
  • OBJECTIVE: Minimal residual disease (MRD) is one of the most important prognostic factors in childhood acute lymphoblastic leukemia (ALL).
  • Using sets of combined antibodies, immunophenotypic expression of leukemia cells was observed in 95 of 106 B-lineage ALL cases (89.6%).
  • [MeSH-major] Flow Cytometry / methods. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Child. Gene Rearrangement, T-Lymphocyte. Humans. Immunophenotyping. Neoplasm, Residual

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374803.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


81. Wang J, Zhan P, Chen B, Zhou R, Yang Y, Ouyang J: MTHFR C677T polymorphisms and childhood acute lymphoblastic leukemia: a meta-analysis. Leuk Res; 2010 Dec;34(12):1596-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MTHFR C677T polymorphisms and childhood acute lymphoblastic leukemia: a meta-analysis.
  • To date, case-control studies on the association between methylenetetrahydrofolate reductase (MTHFR) C677T and childhood acute lymphoblastic leukemia have provided either controversial or inconclusive results.
  • To clarify the effect of MTHFR C677T on the risk of childhood acute lymphoblastic leukemia, a meta-analysis of all case-control observational studies was performed.
  • The random effects (RE) model showed that the 677T allele was not associated with a decreased susceptibility risk of childhood acute lymphoblastic leukemia compared with the C allele [OR=0.96, 95% confidence interval (CI) (0.88-1.04), P=0.34].
  • Although MTHFR C677T was associated with increased risks of colorectal cancer, leukemia, and gastric cancer, our pooled data suggest no evidence for a major role of MTHFR C677T in the carcinogenesis of childhood acute lymphoblastic leukemia.
  • [MeSH-major] Alleles. Methylenetetrahydrofolate Dehydrogenase (NADP) / genetics. Models, Biological. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Case-Control Studies. Child. Child, Preschool. Colorectal Neoplasms / genetics. Female. Homozygote. Humans. Male. Predictive Value of Tests. Risk Factors. Stomach Neoplasms / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20409583.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.5 / Methylenetetrahydrofolate Dehydrogenase (NADP)
  •  go-up   go-down


82. Al-Adnani M, Williams S, Anderson J, Ashworth M, Malone M, Sebire NJ: Immunohistochemical nuclear positivity for WT1 in childhood acute myeloid leukemia. Fetal Pediatr Pathol; 2007 Jul-Aug;26(4):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical nuclear positivity for WT1 in childhood acute myeloid leukemia.
  • Several studies have reported previously that acute myeloid leukemia (AML) may express WT1 detected by RT-PCR and/or Northern blotting.
  • Paraffin-embedded tissue sections from 55 AML, 12 acute lymphoblastic leukemia (ALL), and 10 normal bone marrow specimens were immunostained for WT1 (anti-N terminus antibody).
  • This finding is important for the correct interpretation of immunohistochemical findings in the diagnosis of "small round cell" tumors of childhood, especially in cases of extramedullary deposits of AML, in which traditional myeloid markers may be negative.
  • [MeSH-major] Cell Nucleus / metabolism. Leukemia, Myeloid, Acute / metabolism. WT1 Proteins / metabolism


83. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR, International BFM Study Group (I-BFM-SG): Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia; 2008 Apr;22(4):771-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
  • Detection of minimal residual disease (MRD) is the most sensitive method to evaluate treatment response and one of the strongest predictors of outcome in childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Gene Rearrangement. Neoplasm, Residual. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Gene Rearrangement, T-Lymphocyte. Genes, Immunoglobulin / genetics. Humans. Infant. Polymerase Chain Reaction. Risk Assessment


84. van Vlierberghe P, Meijerink JP, Lee C, Ferrando AA, Look AT, van Wering ER, Beverloo HB, Aster JC, Pieters R: A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia. Leukemia; 2006 Jul;20(7):1245-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia.
  • Over the last decade, genetic characterization of T-cell acute lymphoblastic leukemia (T-ALL) has led to the identification of a variety of chromosomal abnormalities.
  • In this study, we used array-comparative genome hybridization (array-CGH) and identified a novel recurrent 9q34 amplification in 33% (12/36) of pediatric T-ALL samples, which is therefore one of the most frequent cytogenetic abnormalities observed in T-ALL thus far.
  • [MeSH-major] Chromosomes, Human, Pair 9. Gene Duplication. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. In Situ Hybridization, Fluorescence. Infant. Male. Oncogene Proteins, Fusion / genetics. Predictive Value of Tests. Receptor, Notch1 / genetics. Recurrence. Reverse Transcriptase Polymerase Chain Reaction


85. Kroll ME, Draper GJ, Stiller CA, Murphy MF: Childhood leukemia incidence in Britain, 1974-2000: time trends and possible relation to influenza epidemics. J Natl Cancer Inst; 2006 Mar 15;98(6):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukemia incidence in Britain, 1974-2000: time trends and possible relation to influenza epidemics.
  • We investigated time trends in childhood leukemia by using Poisson regression methods to analyze data from the National Registry of Childhood Tumours, a long-standing high-quality registry that covers the whole childhood population of Britain.
  • During 1974-2000, the average annual percentage change in rate (AAC) of childhood acute lymphoblastic leukemia (ALL) in Britain was 0.7% (95% confidence interval [CI] = 0.4 to 1.0).
  • This increase was apparently driven by the "common" subtype (expressing the CD10 antigen) of precursor B-cell ALL, for which the estimated AAC during 1980-1996 was 1.4% (95% CI = 0.8 to 2.0).
  • There was no statistically significant time trend in other subtypes of ALL combined (1980-1996) or in acute myeloid leukemia (1974-2000).
  • These results are consistent with hypotheses that some childhood leukemia may be triggered by infection occurring close to the time of diagnosis of leukemia, particularly in conditions of low herd immunity, and raise the possibility that contact with influenza shortly before the diagnosis of leukemia may sometimes be involved.
  • [MeSH-major] Disease Outbreaks. Influenza, Human / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology
  • [MeSH-minor] Adolescent. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / virology. Child. Female. Great Britain / epidemiology. Humans. Incidence. Male. Poisson Distribution. Registries

  • MedlinePlus Health Information. consumer health - Flu.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Dec 6;98(23):1746; author reply 1746-7 [17148778.001]
  • (PMID = 16537835.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Gökbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2006;:133-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of adult acute lymphoblastic leukemia.
  • In the early 1980s, adult acute lymphoblastic leukemia (ALL) was a rarely curable disease with overall survival < 10%.
  • After adapting combinations employed by pediatric groups, the outcome improved to 30-40%.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124052.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 42
  •  go-up   go-down


87. Goebel WS, Conway JH, Faught P, Vakili ST, Haut PR: Disseminated toxoplasmosis resulting in graft failure in a cord blood stem cell transplant recipient. Pediatr Blood Cancer; 2007 Feb;48(2):222-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of fatal disseminated toxoplasmosis, diagnosed at autopsy, in a 7-year-old boy who received a cord blood graft for recurrent acute lymphoblastic leukemia.
  • [MeSH-minor] Child. Fatal Outcome. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Toxoplasmosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16333839.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Milne E, Laurvick CL, de Klerk N, Robertson L, Thompson JR, Bower C: Trends in childhood acute lymphoblastic leukemia in Western Australia, 1960-2006. Int J Cancer; 2008 Mar 1;122(5):1130-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in childhood acute lymphoblastic leukemia in Western Australia, 1960-2006.
  • Increases in the incidence of childhood acute lymphoblastic leukemia (ALL) have been reported in some countries, while other reports from similar geographical regions have indicated stable rates.
  • We used population-based data from Western Australia to investigate trends in the incidence of childhood ALL between 1960 and 2006.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Australia / epidemiology. Child. Child, Preschool. Female. Humans. Incidence. Male. Registries


89. Nyári TA, Kajtár P, Bartyik K, Thurzó L, McNally R, Parker L: Seasonal variation of childhood acute lymphoblastic leukaemia is different between girls and boys. Pathol Oncol Res; 2008 Dec;14(4):423-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seasonal variation of childhood acute lymphoblastic leukaemia is different between girls and boys.
  • The aim of this study was to investigate seasonal trends in the incidence of acute lymphoblastic leukaemia (ALL) around the times of birth and diagnosis in children aged 0-4 years and also to examine gender specific effects.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Seasons
  • [MeSH-minor] Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Sex Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Epidemiol Community Health. 1999 Apr;53(4):235-8 [10396550.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):549-53 [10507784.001]
  • [Cites] Lancet. 1969 Oct 18;2(7625):826-7 [4186286.001]
  • [Cites] J Community Health. 1982 Spring;7(3):159-70 [7076880.001]
  • [Cites] Br J Cancer. 1997;75(11):1711-3 [9184193.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):406-12 [11161408.001]
  • [Cites] Hematol Oncol. 2003 Jun;21(2):51-5 [12802809.001]
  • [Cites] J Epidemiol Community Health. 1997 Apr;51(2):151-9 [9196644.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):119-24 [9662261.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] Med Pediatr Oncol. 2002 May;38(5):338-44 [11979458.001]
  • [Cites] Pediatr Blood Cancer. 2006 Dec;47(7):944-8 [16421899.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):678 [9484831.001]
  • [Cites] Leuk Res. 2002 Jul;26(7):651-6 [12008082.001]
  • [Cites] Int J Epidemiol. 1992 Apr;21(2):381-6 [1428496.001]
  • [Cites] Lancet. 1989 Feb 18;1(8634):378-9 [2563524.001]
  • [Cites] BMC Public Health. 2003 Mar 24;3:13 [12659651.001]
  • [Cites] Paediatr Perinat Epidemiol. 2001 Oct;15(4):338-45 [11703681.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):812-7 [9514063.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] JAMA. 2001 Jan 10;285(2):168-9 [11176808.001]
  • [Cites] Orv Hetil. 2003 Sep 21;144(38):1869-71 [14596025.001]
  • (PMID = 18409021.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


91. Wananukul S, Nuchprayoon I, Siripanich H: Mucocutaneous findings in febrile neutropenic children with acute leukemias. J Med Assoc Thai; 2005 Jun;88(6):817-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucocutaneous findings in febrile neutropenic children with acute leukemias.
  • Febrile neutropenia is common in children with leukemia.
  • The authors prospectively examined children with fever with neutropenia in acute leukemia, aged 1-15 years, who were admitted to the Department of Pediatrics, King Chulalongkorn Memorial Hospital, between September 2000 and August 2001.
  • Daily physical examination of skin and mucous membrane are suggested for proper and prompt diagnosis and treatment of febrile neutropenic children with acute leukemia to reduce mortality and morbidity in these patients.
  • A Guideline for the use of antimicrobial agents in neutropenic patients with acute leukemia is proposed In conclusion, infection was commonly found in severe neutropenia.
  • Mucocutaneous infection was the most common site of infection infebrile neutropenia in children with leukemia.
  • [MeSH-major] Fever. Neutropenia / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Skin Diseases / etiology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Male. Mucous Membrane / pathology. Prospective Studies

  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083222.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


92. Spinola-Castro AM, Siviero-Miachon AA, Andreoni S, Tosta-Hernandez PD, Macedo CR, Lee ML: Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited. Clin Adv Hematol Oncol; 2009 Jul;7(7):465-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited.
  • Hyperglycemia has been described as a common event occurring during acute lymphocytic leukemia chemotherapy.
  • Our goal was to compare clinical and laboratory findings between hyperglycemic episodes occurring during childhood acute lymphocytic leukemia induction chemotherapy.
  • There were no differences in clinical or laboratory variables among groups, although the majority of episodes occurred in pubescents, regardless of the type of glucocorticoid employed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Glucocorticoids / adverse effects. Hyperglycemia / chemically induced. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Amylases / blood. Blood Glucose / metabolism. Body Mass Index. Child. Child, Preschool. Female. Humans. Infant. Male. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19701154.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Blood Glucose; 0 / Glucocorticoids; EC 3.2.1.- / Amylases
  •  go-up   go-down


93. Ficek K, Blamek S, Syguła D, Miszczyk L, Sońta-Jakimczyk D, Tarnawski R: Evaluation of the late effects of CNS prophylactic treatment in childhood acute lymphoblastic leukemia (ALL) using magnetic resonance spectroscopy. Acta Neurochir Suppl; 2010;106:195-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the late effects of CNS prophylactic treatment in childhood acute lymphoblastic leukemia (ALL) using magnetic resonance spectroscopy.
  • PURPOSE: The aim of the study was to evaluate the late changes seen in Magnetic Resonance Spectroscopy (MRS) of the brain in Acute Lymphoblastic Leukemia (ALL) survivors to assess neurotoxicity following prophylactic treatment with cranial irradiation (CRT) and/or intrathecal (ITMTX) and systemic MTX.
  • CONCLUSION: MRS is a sensitive detector of late metabolic changes after prophylactic treatment for ALL in childhood.
  • [MeSH-major] Brain Injuries. Cranial Irradiation / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Case-Control Studies. Child. Child, Preschool. Choline / metabolism. Creatine / metabolism. Drug Administration Routes. Drug Therapy / methods. Female. Humans. Immunosuppressive Agents / administration & dosage. Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Male. Methotrexate / administration & dosage. Tissue Distribution


94. Harper JD, Shah SK, Baldwin DD, Moorhead JD: Laparoscopic nephrectomy for pediatric giant hydronephrosis. Urology; 2007 Jul;70(1):153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic nephrectomy for pediatric giant hydronephrosis.
  • OBJECTIVES: To describe our experience with pediatric laparoscopic nephrectomy (LN) and laparoscopic nephroureterectomy (LNU) for giant hydronephrosis.
  • METHODS: A retrospective review was conducted of all pediatric patients undergoing a transperitoneal LN or LNU.
  • CONCLUSIONS: Although pediatric LN and LNU for giant hydronephrosis present unique challenges owing to the large renal volume in a small abdominal cavity, these procedures can be safely performed with careful attention to the altered anatomic relationships.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656227.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Singer JS, Ettenger RB, Gore JL, Gritsch HA, Rajfer J, Rosenthal JT, Schulam P: Laparoscopic versus open renal procurement for pediatric recipients of living donor renal transplantation. Am J Transplant; 2005 Oct;5(10):2514-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic versus open renal procurement for pediatric recipients of living donor renal transplantation.
  • Despite reports demonstrating the safety of laparoscopic donor nephrectomy (LDN) for pediatric recipients of renal transplants, recent evidence has challenged using LDN for recipients 5 years of age or younger.
  • We retrospectively reviewed the records of all pediatric recipients of living donor renal transplants from September 2000 through August 2004.
  • Outcomes of interest included operative complications, postoperative renal function, the incidence of delayed graft function or episodes of acute rejection and long-term graft function.
  • Rates of delayed graft function and acute rejection did not differ between groups.
  • At our center, pediatric LDN recipients have graft outcomes comparable to those of ODN recipients.
  • At experienced centers, we recommend continued use of LDN for pediatric recipients of all ages.
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Creatinine / blood. Creatinine / urine. Female. Graft Rejection. Graft Survival. Humans. Kidney / pathology. Living Donors. Male. Nephrectomy / methods. Renal Artery. Retrospective Studies. Time Factors. Tissue and Organ Harvesting / methods. Tissue and Organ Procurement. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162202.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


96. Mahone EM, Prahme MC, Ruble K, Mostofsky SH, Schwartz CL: Motor and perceptual timing deficits among survivors of childhood leukemia. J Pediatr Psychol; 2007 Sep;32(8):918-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Motor and perceptual timing deficits among survivors of childhood leukemia.
  • OBJECTIVE: There is growing evidence of cerebellar-frontal system change in children treated for leukemia with chemotherapy alone (Lesnik et al., 1998).
  • METHODS: We compared 22 long-term survivors of acute lymphoblastic leukemia (ALL), aged 8-18, to 22 age- and gender-matched controls on tasks emphasizing cerebellar-frontal functioning including judgment of time duration and motor timing.
  • CONCLUSIONS: Treatment with intrathecal and infusional chemotherapy for childhood ALL may be associated with skill deficits comparable to those seen in individuals with cerebellar-frontal abnormalities.
  • [MeSH-major] Motor Skills Disorders / epidemiology. Perceptual Disorders / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Survivors
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Cerebellum / physiopathology. Child. Female. Frontal Lobe / physiopathology. Humans. Judgment. Male. Methotrexate / therapeutic use. Reaction Time

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522113.001).
  • [ISSN] 0146-8693
  • [Journal-full-title] Journal of pediatric psychology
  • [ISO-abbreviation] J Pediatr Psychol
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD-24061; United States / NINDS NIH HHS / NS / K02 NS044850; United States / NINDS NIH HHS / NS / K08 NS02039; United States / NCRR NIH HHS / RR / M01 RR00052; United States / NINDS NIH HHS / NS / R01 NS047781
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


97. Dai L, Gast A, Horska A, Schrappe M, Bartram CR, Hemminki K, Kumar R, Bermejo JL: A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes. Pediatr Blood Cancer; 2009 Jul;52(7):819-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes.
  • BACKGROUND: Inherited genetic variants in critical genes can putatively modulate susceptibility to childhood acute lymphoblastic leukemia (ALL).
  • METHODS: We used allelic discrimination method to genotype 19 polymorphisms in the transforming growth factor-beta1 (TGF-beta1), transforming growth factor-beta receptor 1 (TGF-betaR1) and transforming growth factor-beta receptor 2 (TGF-betaR2) genes in 460 cases of childhood acute ALL and 552 ethnically matched controls.
  • No other polymorphism showed any association with childhood ALL susceptibility.
  • CONCLUSION: These data rule out the role of polymorphisms in the TGF-beta1, TGF-betaR1 and TGF-betaR2 genes in susceptibility to childhood ALL.
  • [MeSH-major] Polymorphism, Single Nucleotide / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein-Serine-Threonine Kinases / genetics. Receptors, Transforming Growth Factor beta / genetics. Transforming Growth Factor beta / genetics
  • [MeSH-minor] Adult. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Case-Control Studies. Child. Female. Haplotypes / genetics. Humans. Male. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19229971.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


98. Rivera GK, Zhou Y, Hancock ML, Gajjar A, Rubnitz J, Ribeiro RC, Sandlund JT, Hudson M, Relling M, Evans WE, Pui CH: Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer; 2005 Jan 15;103(2):368-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
  • BACKGROUND: The authors studied the clinical outcome of 106 children with acute lymphoblastic leukemia (ALL) who developed a bone marrow recurrence as the first adverse event after contemporary intensified therapy.
  • CONCLUSIONS: Despite acceptable long-term second EFS rates for certain subgroups, overall bone marrow recurrence after intensified first-line therapy for childhood ALL signals a poor outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / epidemiology. Bone Marrow / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Probability. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Risk Assessment. Severity of Illness Index. Sex Distribution. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15599932.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


99. Hunger SP, Winick NJ, Sather HN, Carroll WL: Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: when do we say enough? Pediatr Blood Cancer; 2005 Dec;45(7):876-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: when do we say enough?
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Child. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Retrospective Studies. Risk Factors


100. Martin FT, O'Sullivan JB, Regan PJ, McCann J, Kelly JL: Hydrocolloid dressing in pediatric burns may decrease operative intervention rates. J Pediatr Surg; 2010 Mar;45(3):600-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydrocolloid dressing in pediatric burns may decrease operative intervention rates.
  • INTRODUCTION: Partial-thickness scalds are the most common pediatric burn injury, and primary management consists of wound dressings to optimize the environment for reepithelialization.
  • AIM: The aim of the study was to retrospectively analyze pediatric burns in a single tertiary referral center over a 10-year period comparing the impact of Jelonet and DuoDERM dressings relative to operative intervention rates.
  • METHODS: All pediatric burns admitted between 1997 and 2007 were identified using the Hospital Inpatient Enquiry system.
  • Acute, partial-thickness burns in patients younger than 15 years were analyzed according to dressing type applied (Jelonet or DuoDERM).
  • RESULTS: Two hundred forty-eight pediatric burns were analyzed between 1997 and 2007.
  • CONCLUSION: Observational evidence suggests that DuoDERM leads to less operative intervention and should be preferentially used in pediatric burns.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Injury Severity Score. Length of Stay. Male. Pain Measurement. Probability. Retrospective Studies. Risk Assessment. Treatment Outcome. Wound Healing / physiology

  • MedlinePlus Health Information. consumer health - Burns.
  • Hazardous Substances Data Bank. PETROLATUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223327.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / jelonet; 8009-03-8 / Petrolatum
  •  go-up   go-down






Advertisement